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Mitochondria are dynamic, double-membrane bound hubs of bioenergetics, cell 
signaling, and redox balance that exist as an oscillating network of fused superstructures 
and smaller, single organelles. Importantly, their position at the junction of catabolic and 
anabolic metabolism connects these morphological fluctuations to larger cellular 
metabolic programs, which in turn have implicated mitochondrial dynamics in a number 
of disease states and a varied set of cell phenomena. For example, differentiation of 
memory t-cells is dependent on mitochondrial network morphology, and in particular on 
remodeling dynamics that yield fused mitochondrial assemblies favoring oxidative 
phosphorylation-driven metabolism. In contrast, many cancers have been shown to de-
emphasize mitochondrial fusion processes through enhanced fission action, which has 
been theorized to be associated with the glycolytic hallmarks of cancer proliferation and 
progression. This dissertation elucidates the diversity of roles mitochondrial dynamics 
and bioenergetics play in defining molecular metabolic schemes across many normal and 
abnormal physiologies, and underscores the importance of the original research we have 
produced within the immunological, oncological, and hepatic domains. In particular, the 
through-lines of our findings on mitochondrial plasticity and remodeling in cancer 
chemotherapy survival mechanisms, t-cell fate, obesity, and hepatocyte injury will be 
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In nearly every mammalian cell there resides the mitochondria, which are 
classically recognized as primary generators of adenosine triphosphate (ATP) (1), storage 
vessels of calcium cations (2, 3), and gatekeepers of cell death via intrinsic apoptosis (4, 
5). Their ubiquity in powering complex life belies their extreme importance across 
species, as does their role in both cell homeostasis and disease pathophysiologies. 
Anatomically they are comprised of outer and inner mitochondrial bi-layered membranes 
(MOM, MIM) surrounding the intermembrane space and matrix, respectively, and their 
proper function requires an estimated 1200 genes. Of these, only a fraction- 37- are 
   a   a  DNA ( DNA)   a  
matrix, with 16,569 base pairs comprising the nuclear encoded remainder. These nuclear 
genes (nDNA) program expression of the majority of mitochondrial proteins, which are 
translated in the cytosol and imported into the mitochondria via various translocases (6, 
7). Their broad and diverse functions in cells are largely enabled by their ability to 
dynamically alter both their 1) morphology and 2) bioenergetic capacity in processes 
collectively referred to here as mitochondrial remodeling. This plasticity plays a dramatic 
role in cell function, and in particular, draws a through-line across each of the conditions 
detailed in this dissertation (and indeed, countless more). However, elucidation of the 
impacts of mitochondrial remodeling on adaptation and response should be preceded by a 





Bioenergetics and the Biochemistry of Electron Transport Proteins (Complexes I – IV) 
 
Cellular ATP is generated primarily through the action of oxidative 
phosphorylation (OXPHOS) by the electron transport system embedded in the IMM, 
which is composed of 5 sequentially structured, multiple-subunit protein complexes 
(Complexes I  V). Within the ETC, both the glycolysis and tricarboxylic pathways 
generate the electron shuttles NADH and FADH2, which donate electrons to NADH-
coenzyme Q oxidoreductase (complex I) and Succinate-Q oxidoreductase (complex II) 
(CI, CII), respectively (8, 9). The reaction catalyzed by CI, which is to say the electron 




The oxidation of succinate to fumarate and subsequent reduction of ubiquinone by CII 




Interestingly, this latter reaction releases less energy than the oxidation of NADH at CI, 
and CII neither pumps protons across the membrane, nor does it contribute to the proton 
gradient.  
S , a     a      Coenzyme Q10, 
which transports them to Q-cytochrome c oxidoreductase (complex III, CIII). CIII 
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catalyzes the oxidation of one molecule of ubiquinol and reduces two molecules of 




Through mediation by cytochrome-c, the electrons are again transferred, this time to 
Cytochrome c oxidase (complex IV, CIV), which catalyzes the final reaction of the ETC 
where the electrons are at last donated to the final embedded electron acceptor (molecular 
oxygen), which is reduced to water. This oxygen provides most of the energy released in 




Throughout this electron transport, energy is released and utilized at CI, CIII, and 
CIV to pump hydrogen cations (H+) from the mitochondrial matrix to the MIM, 
generating a proton motive force employed by Complex V (FoF1-ATP synthase) to allow 
proton rentry to the matrix, catalyzing the phosphorylation of adenosine diphosphate 
(ADP) to form ATP (10, 11) and reactive oxygen species (ROS). In addition, this process 
also creates an electrical gradient membrane potential (Δψm) across the MIM that is 
important in maintaining the ability of CV to generate ATP from ADP (12).  
 
Mitochondrial Anatomy and Mitochondrial Dynamics 
 
The mitochondrion is a double membrane organelle, with the MOM enveloping 
the MIM, which itself possesses several folds (cristae) that increase the MIM surface 
 4 
area. The outer and inner membranes are separated by the inner membrane space (IMS), 
and maintaining the structural integrity of these components is important for functioning 
and efficient OXPHOS and ATP production (13, 14). For example, it has been discovered 
that in its early stages, the assembly of both CIII and CIV transpires at the inner boundary 
membrane, while CV assemblage is performed in the cristae membrane (15). As such, 
alterations to or changes in the cristae structure can directly impact the expression of ETC 
complexes, and indeed, this differential MIM and MOM morphology changes from one 
tissue cell type to another (16, 17, 18, 19). The mechanism of this morphological shifting, 
as well as the process of morphological changes to mitochondria along a time axis, is 
termed mitochondrial dynamics (a type of mitochondrial remodeling), which can be 
bifurcated into mitochondrial fission and fusion; each will be examined more closely 
below. As a result of fission/fusion action, mitochondria exist along an oscillating 
morphological spectrum, from long hyperfused structures to detached circular organelles, 




Mitochondrial fission is mediated by the cytosolic GTPase dynamin-related 
protein 1 (DRP-1) (20), which is dispersed in the cytosol until its recruitment to the 
external surface of the MOM upon the initiation of fission; this process is mediated by 
mitochondrial fission factor (MFF) and fission protein 1 (hFIS1) (21). Once localized to 
the MOM, DRP-1 oligomerizes into a constrictive ring structure, and upon GTP 
hydrolysis, reduces its diameter to effect mitochondrial fission (22, 23). This process can 
be regulated post-translationally through phosphorylation (24, 25), SUMOylation (26), 
and glycosylation (27), though most germane to this dissertation is stimulation through 
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phosphorylation at serine616 (28). A simplified schematic of this process is depicted in 
Figure 1.1. Fission is important not just for mitochondrial separation and inheritance 
since mitochondria cannot be created de-novo (29), but also for other phenomena, 
including mitophagy (30) and apoptosis (31, 32). 
 
 
Outer Mitochondrial Membrane Fusion 
 
 U     a a   , a    
sequential merging of both the MOM and MIM, in that order. In MOM fusion, the 
process is mediated by hetero- or homo-typic interactions of the mitochondrial fusion 
GTPase proteins mitofusin-1 (MFN-1) and mitofusin-2 (MFN-2) that are located on the 
MOM of each mitochondria (33, 34, 35, 36). Both mitofusins are transmembrane in that 
their N-terminus face outward from the MOM into the cytosol, while their C-terminus 
face into the intermembrane space; the interaction between them is believed to be via the 
formation of disulfide bridges (37). This interaction exerts a pulling motion on each 
MOM, effectively merging them. A simplified schematic of this process is depicted in 
Figure 1.2. Interestingly, both MFN-1 and MFN-2 have been found to be important to 


























Figure 1.1. Broad, simplified schematic of DRP-1 mediated mitochondrial fission. Activated DRP-1, 
which are those phosphorylated at serine 616, localizes to the MOM of target mitochondrion, oligomerizes 




















 Inner Mitochondrial Membrane Fusion 
 
 MIM fusion occurs subsequentially to MOM association, and is dependent on the 
action of the GTPase optic atrophy 1 (OPA-1) (31,39), which exists as eight unique 
isoforms on account of splicing differentials (40). Despite domain differences between 
isoforms, each contain a mitochondrial targeting sequence and a protease cleavage site, 
denoted as S; half of the eight isoforms also include an additional cleavage site, denoted 
S2 (40). With MIM fusion, the mitochondrial targeting sequence is cleaved, resulting in 
an MIM long OPA-1 form. Further subsequent cleavage at the S1 or S2 sites produces 
OPA-1 short forms, and since both long and short forms of OPA-1 are required for proper 
MIM fusion, this proteolytic activity on OPA-1 has been identified as an important 
regulatory mechanism (41). However, in addition to its role in fusion, OPA-1 has been 
found to be directly involved in cristae and membrane structure, and knockout models 
have produced mitochondrial fragmentation, loss of m, and cytochrome-c release, 






















Figure 1.2. Broad, simplified schematic of MFN-1,2 and OPA-1 mediated mitochondrial fusion. 
Mitofusins 1 and 2 associate homo- or hetero-typically to mediate merging of the MOM. OPA-1 




















Potential Role of Complex V in MIM Structure 
 
Dimerization of CV has been demonstrated to induce MIM cohesion and 
curvature (43), and disassociation studies found corroborating instances of cristae 
structure aberrations (44). It has since been proposed that such dimerization is driven by 
a   CV  F1 domains mediated by the ATPase inhibitory factor 1 (If1) (45), as 
If1 knockout decreased cristae density (46). Moreover, in yeast it has been found that 
dimerization of CV is positively correlated to demand of ATP generated through 
OXPHOS (47).  
 
   
Selected Effects of Mitochondrial Morphological and Bioenergetic Remodeling 
 
 
The importance of mitochondrial dynamics/morphological remodeling protein 
mediators has been made evident both through mutation and mitochondrial function 
studies. As a limited example, changes to and modifications of mitochondrial activity 
 a  a  a   a   H  D a  (48),  
disease (49), ischemia/reperfusion injuries (50), A  D a  (51),  (52), 
and, of particular relevance to chapter 4 of this dissertation, cancer (53). Similarly, 
bioenergetic remodeling has been found to play important roles both in disease and 
protection physiologies. In diabetic cardiomyopathy, mitochondrial organization greatly 
enhances oxidative phosphorylation energy supply (54), and in starvation-induced 
autophagy, DRP-1 is barred from translocating to the MOM, helping maintain cristae and 
ATP production, with the mitochondria expressing higher amounts of CV increasing their 
OXPHOS activity and rescuing themselves from autophagy-driven mitophagy and 
degradation (55). 
 10 
These paradigms represent only a small fraction of the diversity of roles that 
mitochondrial remodeling and plasticity play in several disease models, and serve as a 
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CHAPTER 1:  
OBESITY AND STEATOSIS PROMOTES MITOCHONDRIAL REMODELING 







We investigated if obesity/steatosis promotes mitochondrial remodeling in the 
liver of ob/ob mice (an obesity model). Liver mitochondria from ob/ob mice (21 weeks 
with significant steatosis) has ~ 2-fold increases in state III respiration compared with 
control (C57BL/6J, C57BL/6NJ) for all respiratory subtrates examined 
(glutamate/malate, succinate, octanoate, and glycerol 3-phosphate). A corresponding 2-
fold increase in the expression of respiratory complexes (I, IV, and V) and other 
respiratory proteins (glycerol phosphate dehydrogenase-2 and medium-chain acyl-
coenzyme A dehydrogenase) occur in liver mitochondria of mature ob/ob mice. 
Conversely, respiration in liver mitochondria from young ob/ob mice (6 weeks) does not 
differ from control with any respiratory substrates examined. Overall, mitochondrial 






Mitochondria are dynamic organelles that readily adapt to meet the energy 
requirements of cells (1, 2, 3). Many stresses, such as exercise, have been shown to 
increase mitochondrial respiratory capacity to increase ATP production in various cells 
and tissues (4, 5, 6). The enhanced mitochondrial bioenergetic capacity that occurs with 
various stresses is mediated by mitochondrial biogenesis, alteration in mitochondrial 
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fusion-fission (generation of elongated mitochondria with greater cristae surface area), or 
increased expression of respiratory complex proteins (2, 7, 8, 9). The latter involves 
increased expression of select complexes, mainly complex I (NADH dehydrogenase) or 
complex IV (cytochrome oxidase), rather than all proteins in the electron transport chain 
(ETC). Complex I has been shown to be stoichiometrically lower compared with the 
other complexes, and its increased expression can increase mitochondrial respiration 
driven by NADH (10, 11). Similarly, complex IV activity has been suggested to be rate 
limiting in mitochondrial respiration, and increased expression of complex IV can 
enhance mitochondrial respiration (12, 13). The mitochondrial remodeling caused by 
increased expression of select respiratory proteins in the ETC may, there- fore, be an 
important mechanism to regulate mitochondrial bioenergetic activity and ATP production 
in cells. Mitochondrial remodeling, mitochondrial plasticity, or mitoplasticity are terms 
that have been used to describe the dynamic and adaptive nature of mitochondria (9, 14, 
15). 
Mitochondrial remodeling may be an important mechanism that helps the liver 
adapt to various stresses and metabolic changes (2, 15). Our recent findings have shown 
that mitochondrial remodeling in the liver may be an important adaptation to chronic 
alcohol feeding by enhancing NAD+ regeneration needed for alcohol metabolism (9, 15). 
Traditionally, alcoholic liver disease has been suggested to involve mitochondrial 
dysfunction (16, 17, 18), primarily based on studies involving oral alcohol feeding to rats 
(via the Lieber-DeCarli diet). These studies have demonstrated that alcohol feeding 
causes a decline in mitochondrial respiration (complexes I- and II-driven state III 
respiration) and a decline in the respiratory control ratio (RCR) in liver mitochondria (19, 
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20, 21). Our detailed investigation of mitochondrial changes in this rat alcohol model 
showed that while there are some mitochondrial declines (i.e. succinate-driven 
respiration), there was also a great deal of mitochondrial remodeling associated with 
enhanced respiration utilizing other mitochondrial substrates (i.e. glycerol 3-phosphate 
(G3P), octanoate) (15). Mitochondrial alterations in the liver caused by alcohol also 
appear to be very model dependent, as alcohol feeding to mice only increases 
mitochondrial respiration and does not cause any of the declines in mitochondrial 
bioenergetic activity that are observed in rats (9).  
Overall, in both mice and rats, greater alcohol-induced steatosis (fatty liver) was 
associated with greater mitochondrial remodeling (9, 15). Since some mitochondrial 
remodeling (i.e. enhanced activity of mitochondrial enzymes) has been reported to occur 
in the liver of alcoholic patients (22), mitochondrial remodeling may have clinical 
significance in humans. The mitochondrial alterations that occur in the liver during 
nonalcoholic fatty liver disease (NAFLD) have been controversial. Studies using various 
animal models of NAFLD have shown either declines in mitochondrial bioenergetic 
activity, no changes in activity, or increases in mitochondrial bioenergetic activity in the 
liver (23, 24, 25, 26, 27). Even within the same model, such as with ob/ob mice (an 
obesity model caused by a leptin deficiency that decreases energy expenditure and 
increases caloric intake), mitochondrial alterations in liver have been reported to be 
vastly different. Several works have suggested that mitochondrial bioenergetic activity 
declines (decreased activity of respiratory complexes, decreased respiration) in the liver 
of ob/ob mice (28, 29), while other studies have shown that mitochondrial bioenergetic 
capacity is enhanced (24, 30). Interestingly, one study observed that leptin treatment to 
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ob/ob mice, which causes weight loss and decreases steatosis, caused a decline in 
mitochondrial respiration in the liver (24). Similarly, a microarray study also found that 
leptin treatment decreased the expression of mitochondrial proteins in the liver in ob/ob 
mice (30). These studies suggest that there may be a strong link between obesity/steatosis 
in ob/ob mice, with weight loss (decline in steatosis) causing a decline in mitochondrial 
respiratory capacity in the liver. 
In this work, we provide a detailed examination of the relationship between 
obesity/steatosis and mitochondrial respiratory capacity in ob/ob mice by examining 
many key bioenergetic parameters, including often overlooked measurements such as 
G3P-driven respiration. We also investigated mitochondrial remodeling in ob/ob mice at 
early (slight steatosis) and later ages (high steatosis) to determine how liver mitochondria 
alter with obesity and steatosis. To our knowledge, our investigation presents the first 









Ob/ob, C57BL/6J, and C57BL/6NJ mice were obtained from Jackson Laboratory 
(Bar Harbor, ME, USA) at 6 weeks of age. The animals were housed in a temperature-
controlled room and were acclimatized for a minimum of 3 days prior to use in 
experiments. All mice were fed standard chow (ad libitum) for up to 22 weeks. The mice 
received care according to methods approved under institutional guidelines for the care 
and use of laboratory animals in research. 
 23 
Isolation of liver mitochondria  
 
Liver mitochondria from mice were isolated using differential centrifugation as 
previously described (31). Livers were excised, washed with 0.25 M sucrose and 
homogenized in an H-medium (210 mM mannitol, 70 mM sucrose, 2 mM HEPES, 0.05% 
bovine serum albumin (w/v)), plus protease and phosphatase inhibitors. The homogenate 
was centrifuged at 1000 g for 10 min, the pellet was removed, and the centrifugation 
process was repeated. The resulting supernatant was centrifuged at 10 000 g for 15 min. 
The pellet, which represents the mitochondria fraction, was washed with H-medium and 
the centrifugation was repeated. The mitochondria were resuspended in H-medium before 
oxygen electrode and western blot analysis.  
 
Measurements of respiration in isolated mitochondria  
 
Respiration was measured in freshly isolated mitochondria by monitoring oxygen 
consumption with a Clark-type electrode (Hanstech, UK) in respiration buffer containing 
230 mM mannitol, 70 mM sucrose, 30 mM Tris HCl, 5 mM KH2PO4, 1 mM EDTA, pH 
7.4 (9). Isolated mitochondria (0.50 mg) were added to 1 mL of respiration buffer and 
oxygen consumption monitored in the presence of mitochondrial substrates 
(glutamate/malate 7.5 mM  complex I substrates; succinate 7.5 mM  complex II 
substrates) with or without ADP (250 lM). Mitochondrial respiration was also measured 
using glycerol 3-phosphate (2.5 mM), which feeds into glycerol phosphate 
dehydrogenase-2 in the mitochondrial inner membrane, and octanoate (200 lM), a 
medium-chain fatty acid that undergoes beta-oxidation. State IV respiration is defined as 
respiration in the presence of substrate, while state III respiration in is defined as 
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respiration in the presence of both substrates plus ADP. The RCR is defined as state 
III/state IV. The ADP/oxygen ratio (P/O ratio) was determined by measuring the total 




Aliquots of cytoplasmic or mitochondrial extracts were fractionated by 
electrophoresis on 8 12% SDS polyacrylamide gels (BioRad, Hercules, CA). 
Subsequently, proteins were transferred to nitrocellulose or PVDF membranes and blots 
were blocked with 5% (w/v) nonfat milk dissolved in Tris-buffered saline (TBS) with 
Tween- 20. Complexes I (NDUFS3 subunit), II (SDHA subunit), complex III (subunit 1), 
V (a subunit), and MCAD anti- bodies were obtained from Mitosciences (Eugene, OR). 
Complex IV and acetylated lysine antibodies were obtained from Cell Signaling 
Technology (Danvers, MA). Although immunoblotting only examines one subunit of the 
select complexes, there appears to be a very strong correlation between our 
immunoblotting data and published BN-PAGE data, which examines all proteins in the 
respiratory complexes. (15). The TFAM antibody was obtained from Avia Systems 
Biology (San Diego, CA). Mitochondrial glycerol phosphate dehydrogenase-2 (GPD2) 
was obtained from Proteintech (Chicago, IL). GPD2 was found in both the dimer (~ 136 
kD) and monomer (~ 68 kD) forms, and liver samples were treated with four times SDS 
to convert the dimer into the monomer form, as previously described (15). All blots 
shown are representative samples from 3 to 7 experiments. Densitometry was performed 
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Mitochondrial remodeling of respiratory proteins in the liver of ob/ob mice (21 weeks)  
 
Ob/ob mice are C57BL/6J mice that spontaneously developed a mutation in 
leptin, leading to increased food intake, obesity, and steatosis. C57BL/6J mice (J mice) 
also harbor another mutation that inactivates nicotinamide nucleotide transhydrogenase 
(NNT), a mitochondrial protein on the inner membrane responsible for transferring 
reducing equivalents from NADH to NADPH (32). To examine if this NNT mutation 
affects mitochondrial remodeling, we also examined mitochondrial bioenergetic activity 
in another control strain (C57BL/6NJ mice  NJ mice), which contain functional NNT 
proteins. We examined mitochondrial alterations in ob/ob mice and control mice at 21 
weeks, when liver steatosis is significant, with only some early markers of steatohepatitis 
in ob/ ob mice (33, 34). Table 1 shows that at 21 weeks, ob/ ob mice have severe 
hepatomegaly (liver/weight ratio) due to steatosis compared with J and NJ mice, in 
agreement with previous results (33, 34).  
Mitochondrial respiration can be assessed by utilizing various respiratory 
substrates that enter the ETC through different proteins (Fig. 1). We first examined the 
mitochondrial respiration using substrates that feed into complex I (glutamate/malate) 
and complex II (succinate) in 21-week-old ob/ob and control mice (J and NJ mice). Fig. 
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2A shows that both glutamate/ malate- and succinate-driven respiration were significantly 
enhanced in liver mitochondria from ob/ob mice, by greater than 2-fold compared with 
both J and NJ mice (*P < 0.05 versus J, ^P < 0.05 versus NJ). No significant differences 
in respiration were observed between J and NJ mice, suggesting that the NNT mutation in 
the J mice did not significantly affect mitochondrial respiration in the liver. Although 
mitochondrial respiration increased in ob/ob mice, no differences in the respiratory 
control ratio (RCR) were observed between the mice strains (Fig. 2B). Similarly, no 
significant differences in the P/O ratio were observed between the three mice strains 
using gluta- mate/malate (J = 2.41 0.33, Ob = 2.58  0.29, NJ = 2.51  0.41) and succinate 
(J = 1.39  0.37, Ob = 1.61  0.31, NJ = 1.58  0.29). The lack of change in RCR and P/O 
ratio in ob/ob mice suggests no uncoupling of mitochondria occurred despite respiration 
being significantly enhanced.  
The increased respiration observed in liver mitochondria from ob/ob mice may be 
due to remodeling of the ETC, as we observed significant increases in the expression of 
complexes I, IV, and V in liver mitochondria from ob/ob mice compared with control 
(Fig.3A,B). Complexes I and IV in particular increased ~ 2-fold in ob/ob mice compared 
with both J and NJ mice. A modest increase in complex II expression in liver 
mitochondria from ob/ob mice was observed, but it was only statistically significant 
when compared with mitochondria from J mice, and not to NJ mice (Fig. 3A,B). No 
significant differences in the expression of respiratory complexes in liver mitochondria 
















































Figure 1. Flow of electrons from respiratory substrates into the ETC. Various respiratory substrates can 
feed electrons into ETC via ubiquinone. Glutamate/malate treatment, through the action of various 
dehydrogenates such as glutamate and malate dehydrogenase, generates NADH that feeds into complex I, 
while succinate feeds into complex II (succinate dehydrogenase). The glycerol phosphate shuttle transfers 
electrons from NADH generated in the cytoplasm into the electron transport chain. Cytoplasmic glycerol 
phosphate dehydrogenase-1 (GPD1) transfers electrons from NADH to dihydroxyacetone phosphate to 
form glycerol-3-phosphate (G3P). G3P then feeds electrons into the ETC through mitochondrial glycerol 
phosphate dehydrogenase-2 (GPD2) in the inner membrane. Beta-oxidation of fatty acids generates 
FADH2 through the action of various acyl-coenzyme A dehydrogenase, such as medium-chain acyl-
coenzyme A dehydrogenase (ACADM). FADH2 feeds into the respiratory chain through electron-
transferring flavoprotein (EFT) and EFT-ubiquinone oxidoreductase. Octanoate-driven respiration depends 











Mitochondrial remodeling of other proteins that feed electrons into the ETC in ob/ob 
mice (21 weeks)  
We next examined mitochondrial respiration using substrates that bypass complex 
I or II and feed electrons into the ETC through other inner membrane proteins (Fig. 1). 
Mitochondrial glycerol phosphate dehydrogenase-2 (GPD2) shuttles electrons from 
NADH generated in the cytoplasm into the ETC (35, 36). Mitochondrial respiration 
utilizing G3P, the substrate that feeds into GPD2 (Fig. 1), was significantly enhanced 
(greater than 2-fold) in isolated liver mitochondria from ob/ob mice compared with both J 
and NJ controls (Fig. 4A).  
We subsequently examined mitochondrial respiration utilizing octanoate, a 
medium-chain fatty acid, that undergoes beta-oxidation in mitochondria through the 
action of medium-chain acyl-coenzyme A dehydrogenase (ACADM; MCAD). Acyl-CoA 
dehydrogenases are a family of enzymes involved in beta-oxidation of fatty acids that 
generate FADH2 that feeds into the respiratory chain through electron-transferring 
flavoprotein (ETF) and ETF-ubiquinone oxidoreductase (Fig. 1). Octanoate-driven 
respiration was significantly increased in isolated liver mitochondria from ob/ob when 
compared with J mice, but not with NJ mice. The increase in octanoate- driven 
respiration in liver mitochondria from ob/ob was ~ 50% compared with control mice, 
much less than the 2-fold increases observed with G3P, succinate, and glutamate/malate. 
Again, no significant differences in respiration were observed between J and NJ mice, 
although in all cases a general trend of a slight decline in mitochondrial respiration was 
observed in J mice compared with NJ mice. No differences in the RCR were observed 
between mice strains with octanoate- and G3P-driven respiration again suggesting no 
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mitochondrial uncoupling (Fig. 4B). G3P and octanoate generally produce lower state III 
respiratory rates than complex I and II substrates, and G3P also has a lower RCR than 
other respiratory substrates (15).  
The increase in octanoate- and G3P-driven respiration in liver mitochondria of 
ob/ob mice may be due to increases in the expression of complex IV (a rate limiting 
respiratory complex (12)), as well as increased expression of ACADM and GPD2, 
respectively (Fig.5A,B). Protein levels of both GPD2 and ACADM were increased ~ 2-
fold compared with both J and NJ mice. The expression of short-chain acyl- coenzyme A 
dehydrogenase (ACADS) was not increased in ob/ob mice liver, demonstrating that not 
all proteins involved in beta-oxidation are increased in ob/ob mice. Liver mitochondria 
from ob/ob mice also had increased expression of mitochondrial transcription factor A 
(TFAM), a key transcription factor (nu- clear gene) that is important for transcribing 
genes from mtDNA (37) (Fig. 5). Increased TFAM expression suggests that transcription 
may be more active in liver mitochondria of ob/ob mice than controls. Over- all, our data 
suggest that there is extensive remodeling of liver mitochondria in ob/ob mice that 



















Figure 2. Liver mitochondria from ob/ob mice (21 weeks) have enhanced complex I- and II-dependent 
respiration compared with controls. (A) State III respiration in isolated liver mitochondria. White bars = 
C57BL/6J (J); stripe bars = ob/ob (Ob); dark gray bars = C57BL/6NJ (NJ). State III respiration was 
measured using either complex I substrates (glutamate/malate, 7.5 mM) or complex II substrate (succinate, 
7.5 mM) in the presence of ADP (250 lM) with an oxygen electrode. (B) Respiratory control ratio (RCR) in 
isolated liver mitochondria. RCR is defined as state III respiration/ state IV respiration ratio. Mice were 
killed at 21 weeks of age and liver mitochondria were isolated using differential centrifugation as described 
in the materials and methods section. N = 5 7 mice per group. Results are mean  SD; *P < 0.05 versus J. ^P 













Increased acetylation of mitochondria protein in the liver in ob/ob mice  
 
Acetylation is a reversible post-translational protein modification involving the 
addition of acetyl groups to lysine residues, which can modulate protein function and 
activity (38, 39). Chronic alcohol feeding, caloric restriction, and other metabolic 
changes have been shown to increase acetylation of mitochondrial proteins in the liver (9, 
15, 40, 41). Similarly, we observed that ob/ob mice had significantly greater acetylation 
in isolated liver mitochondria compared with controls (Fig. 6). Acetylation was mainly 
observed in 2 proteins near 37 kDa and one band near 25 kDa, which all increased ~ 2-
fold in liver mitochondria of ob/ob mice compared with controls.  
 
Mitochondrial remodeling is not observed in young ob/ob mice (6 weeks)  
 
To determine whether mitochondrial remodeling in the liver is inherent in ob/ob 
mice, or develops as ob/ob become more obese and develop steatosis, we examined liver 
mitochondria of young ob/ob mice (6 weeks). Since our earlier experiments showed no 
significant differences in mitochondrial bioenergetics between J and NJ mice, we utilized 
only J mice (background of ob/ob mice) as the controls. At 6 weeks, ob/ob had 
significant greater body and liver weight than J control mice (Table 2), although increases 
in hepatomegaly (liver/ body ratio) were not statistically significant. In these young ob/ob 
mice, no differences in mitochondrial respiration compared with J mice were observed 
with any respiratory substrates examined (Fig. 7A). Similarly, no differences in the 
expression of respiratory complexes were observed compared with J mice (Fig. 7B), 
while densitometry showed no significant differences between the two mice strains (data 
not shown). The RCR also did not differ between ob/ob and J mice (Fig. 7C). Little 
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change in expression of mitochondrial proteins in the liver was observed in J mice with 
age, but many key proteins, such complexes I and IV, significantly increased in ob/ob 
mice as they became more obese and developed greater steatosis (7D; 6 weeks versus 21 
weeks). Complex III was used as the loading control since it has not been shown to be 



































Figure 3. Liver mitochondria from ob/ob mice (21 weeks) have increased the levels of respiratory complex 
proteins. (A) Immunoblots of respiratory complexes (Com) in isolated liver mitochondria. White bars = 
C57BL/6J (J); stripe bars = ob/ob (Ob); dark gray bars = C57BL/ 6NJ (NJ). Mice were killed at 21 weeks 
of age, mitochondria were isolated using differential centrifugation, and mitochondrial protein levels were 
assessed by western blotting. (B) Densitometry of immunoblots for respiratory complexes. Ornithine 
transcarbamylase (OTC) was used as the loading control after it was observed not to be variable between 
mice species. All blots shown are representative samples from 3 to 6 experiments. Densitometry was 
performed using Image J. N = 5 7 mice per group. Results are mean  SD; *P < 0.05 versus J. ^P < 0.05 






















Mitochondrial remodeling of the ETC in the liver of ob/ob mice  
 
Our data, therefore, suggest that similar to the alcohol feeding to mice, as fats 
accumulate in the liver of ob/ob mice, greater mitochondrial remodeling that enhances 
respiration occurs. Interestingly, ob/ob at 21 weeks had a ~ 2-fold increase in respiration 
(e.g. glutamate/ malate, succinate, G3P, octanoate), which corresponded with a ~ 2-fold 
increase in key respiratory proteins in the ETC (complexes I, IV, V, GPD2, ACADM). 
These mitochondrial proteins are the same ones that we observed to increase with 
intragastric alcohol feeding to mice (C57BL/6J), which develop significant steatosis 
similar to that of ob/ob mice (9). Overall, mitochondrial alterations in ob/ob mice and 
intragastric alcohol fed mice seem very similar in terms of increases in mitochondrial 
respiration, increased expression of respiratory proteins, and acetylation of mitochondrial 
proteins. These similarities may not be completely surprising, since alcoholic fatty liver 
disease and NAFLD share many pathologic features (42). Taken together, the data 
suggest that mitochondrial remodeling involving a selective increase in respiratory 
proteins such as complexes I and IV may be an important adaptive mechanism to 
steatosis in the liver.  
The findings of these papers are in agreement with previous studies that 
demonstrate ob/ob mice that were administered leptin, which causes weight loss and 
decreases steatosis, experience decreased mitochondrial respiration and decreased 







Figure 4. G3P- and octanoate-driven respiration is enhanced in liver mitochondria from ob/ob mice (21 
weeks). (A) State III respiration using G3P and octanoate as respiratory substrates. White bars = C57BL/6J 
(J); stripe bars = ob/ob (Ob); dark gray bars = C57BL/6NJ (NJ). State III respiration was measured using 
either G3P (2.5 mM) or octanoate (200 lM) as respiratory substrates in an oxygen electrode in the presence 
of ADP (250 lM). (B) RCR using G3P and octanoate as respiratory substrates. RCR is defined as state III 
respiration/state IV respiration ratio. Mice were killed at 21 weeks of age and liver mitochondria were 
isolated using differential centrifugation as described in Materials and Methods section. N = 5 7 mice per 






We similarly see this relationship, though in a different sequence, as we observed 
with weight gain and development of greater steatosis in ob/ ob mice, extensive 
mitochondrial remodeling and enhanced respiration occurs in the liver. 
It is not clear why these findings that show enhanced mitochondrial respiration 
with obesity are in stark contrast with other studies that suggest a significant decline in 
mitochondrial function in the liver of ob/ob mice. These studies examined different 
mitochondrial parameters (activities of individual complexes, whole liver respiration) 
(28, 29), but these differences should not cause such significant variances with respiration 
measurements reported in this and other studies. The age of experimental mice, their 
genetic background, pathology, and a wide range of other parameters may need to be 
investigated to understand the variations in mitochondrial function in the liver that have 
been reported in ob/ob mice.  
In humans, there is strong evidence that obesity increases mitochondrial 
bioenergetic capacity in the liver. One study observed greater than a 5-fold increase in 
respiration in isolated liver mitochondria from obese patients, with and without steatosis 
(43). Interestingly, this study also found that patients with steatohepatitis (NASH; fatty 
liver plus inflammation) had a 30 40% decline in respiration of liver mitochondria. Most 
stud- ies that have analyzed mitochondria in NASH patients generally report declines in 
mitochondrial protein or respiration (44, 45). Taken together, it appears that mitochondria 
are very dynamic in the liver and appear to increase with obesity and NAFLD, but 
severely decline with the development of NASH (45). One important difference between 
ob/ob mice and humans is that increased mitochondrial respiration in the liver of humans 
has been associated with declines in the RCR. This suggests that there is increasing 
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uncoupling of mitochondria in humans with increase obesity, which causes many 
physiological changes including the generation of heat. It is possible that liver 
mitochondria from ob/ob mice may become more uncoupled as steatosis and obesity 
































Figure 5. Expression of mitochondrial proteins are altered in ob/ob mice (21 weeks). (A) Immunoblots of 
isolated liver mitochondria. White bars = C57BL/6J (J); stripe bars = ob/ob (Ob); dark gray bars = 
C57BL/6NJ (NJ). ACADM, acyl-coenzyme A dehydrogenase medium-chain; ACADS, acyl-coenzyme A 
dehydrogenase short-chain; GPD2, mitochondrial glycerol phosphate dehydrogenase-2; TFAM, 
mitochondrial transcription factor A. G3P feeds electrons into the respiratory chain through GPD2, while 
octanoate feeds electrons through ACADM. Mice were killed at 21 weeks of age, mitochondria were 
isolated using differential centrifugation, and mitochondrial protein levels were assessed by western 
blotting. (B) Densitometry for immunoblots of isolated liver mitochondria. Ornithine transcarbamylase 
(OTC) was used as the loading control after it was observed not to be variable between mice species. 
Densitometry was performed using Image J. N = 5 7 mice per group. Results are mean  SD; *P < 0.05 








This work also explored the possibility that NNT may affect mitochondrial 
remodeling and respiration in the liver. There was a general trend of J mice (NNT 
mutation) having slightly lower mitochondrial respiration and expression of respiratory 
proteins than NJ mice (normal NNT). Much greater numbers of mice will need to be 
utilized to determine if a mutation in NNT significantly affects mitochondrial 
bioenergetics in the liver, since any differences, if they exist, are minimal. It is more 
likely differences in mitochondrial function between J and NJ mice may develop with 
stress, as certain stresses have been shown to cause varying responses in the liver of J and 






























Figure 6. Acetylation of mitochondrial proteins is increased in the liver of ob/ob mice (21 weeks). (A) 
Immunoblots of acetylated mitochondrial proteins (acetylated lysine) from isolated liver mitochondria. 
White bars = C57BL/6J (J); stripe bars = ob/ob (Ob); dark gray 
bars = C57BL/6NJ (NJ). Mice were killed at 21 weeks of age, mitochondria were isolated using differential 
centrifugation, and mitochondrial acetylation was assessed by western blotting. (B) Densitometry for 
mitochondrial acetylation. Ornithine transcarbamylase (OTC) was used as the loading control after it was 
observed not to be variable between mice species. Densitometry was performed using Image J. N = 5 7 


















































Physiologic and pathophysiologic role of mitochondrial remodeling in the liver of ob/ob 
mice  
 
Why do liver mitochondria develop an enhanced respiratory capacity with obesity 
in mice and humans? We hypothesized that chronic alcohol feeding enhances 
mitochondrial respiration to increase NAD+ regeneration needed for alcohol metabolism 
(9, 15). However, the increase in mitochondrial respiration in the liver of obese mice is 
puzzling since there appears to be no metabolic need for such an increase in 
mitochondrial capacity. On the contrary, with excess energy in the form of free fatty 
acids being built up in the liver, it would be predicted that mitochondrial respiration in 
the liver should decline. One possibility is that mitochondrial remodeling occurs to 
increase the beta-oxi- dation potential of the liver as an adaptation to the buildup of fatty 
a . T   a   a    a-oxidation so that fatty acids can be rapidly 
mobilized for energy in the liver when needed. Clearly, more work needs to be performed 
to explore this and other hypotheses for why mitochondrial remodeling in the liver 
increases with obesity. 
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Figure 7. Liver mitochondria from young ob/ ob mice (6 weeks) are similar to control mice. (A) State III 
respiration in isolated liver mitochondria from 6-week-old mice. Solid bars = 6 week-old C57BL/6J (J) 
mice; horizontal stripe bars = 6-week-old ob/ob (Ob) mice. State III respiration was measured using either 
complex I substrates (glutamate/malate, 7.5 mM), complex II substrate (succinate, 7.5 mM), or GPD2 
substrate (G3P 2.5 mM) in the presence of ADP (250 lM) with an oxygen electrode. (B) Immunoblots of 
respiratory complexes (I V) in isolated liver mitochondria from 6-week-old mice. (C) Respiratory control 
ratio (RCR) of isolated liver mitochondria from young mice. (D) Comparison expression of mitochondrial 
proteins from 6-week-old (6J, 6 ob) and 21-week-old mice (21J, 21Ob) using immunoblotting. Complex III 
was used as the loading control after it was observed not to be altered even in mature ob/ob mice. All blots 






While mitochondrial remodeling to increase mitochondrial respiration in the liver 
may represent an unknown adaptation, it may still have pathologic con- sequences. Long-
term increased mitochondrial respiration may promote liver injury through increased 
reactive oxygen species (ROS) generation that may be promoted by the acetylation of 
mitochondrial proteins in the liver of ob/ob mice. Acetylation of mitochondrial proteins 
such as complex I and Mn-superoxide dismutase (Mn-SOD; SOD-2) have been suggested 
to modulate protein activity and increase ROS generation, the latter through inactivation 
of its antioxidant action (38, 46). The levels of acetylation in mitochondria are regulated 
by sirtuin-3 (Sirt-3), the major de-acetylating enzyme in mitochondria (38, 39). How the 
activity of Sirt-3 is affected by obesity in ob/ob mice needs further investigation. There 
is, however, some controversy pertaining to the role of acetylation of mitochondrial 
proteins in regulating mitochondrial ROS generation and bioenergetic activity. Studies 
that have reported that acetylation of mitochondrial proteins decreases mitochondrial 
respiration and increases mitochondrial ROS generation were mainly observed with 
germline Sirt-3 knockout mice (38, 46). However, work with muscle and liver-specific 
Sirt-3 knockout models have demonstrated that increased acetylation of liver 
mitochondria does not affect mitochondrial bioenergetic activity and ROS generation in 
their respective tissues (47). More research exploring the significance of acetylation in 









Overall, mitochondria are very dynamic in the liver and various stresses including 
obesity in mice promote mitochondrial remodeling that enhances mitochondrial 
respiration. Similar mitochondrial remodeling has been seen in human liver tissue in both 
obese and alcoholic patients, suggesting it has important clinical implications (45). Why 
mitochondrial respiratory capacity increases when energy is at an excess remains 
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 MITOCHONDRIAL REMODELING IN THE LIVER FOLLOWING CHRONIC 




The feeding of alcohol orally (Lieber-DeCarli diet) to rats has been shown to 
cause declines in mitochondrial respiration (state III), decreased expression of respiratory 
complexes, and decreased respiratory control ratios (RCR) in liver mitochondria. These 
declines and other mitochondrial alterations have led to the hypothesis that alcohol 
 a  a     . I  a  a   a   
mitochondrial dysfunction, one would predict that increasing alcohol delivery by 
intragastric (IG) alcohol feeding to rats would cause greater declines in mitochondrial 
bioenergetics in the liver. In this study, we examined the mitochondrial alterations that 
occur in rats fed alcohol both orally and intragastrically. Oral alcohol feeding decreased 
glutamate/malate-, acetaldehyde- and succinate-driven state III respiration, RCR, and 
expression of respiratory complexes (I, III, IV, V) in liver mitochondria, in agreement 
with previous results. IG alcohol feeding, on the other hand, caused a slight increase in 
glutamate/malate-driven respiration, and significantly increased acetaldehyde-driven 
respiration in liver mitochondria. IG feeding also caused liver mitochondria to experience 
a decline in succinate-driven respiration, but these decreases were smaller than those 
observed with oral alcohol feeding.  
Surprisingly, oral and IG alcohol feeding to rats increased mitochondrial 
respiration using other substrates, including glycerol-3-phosphate (which delivers 
electrons from cytoplasmic NADH to mitochondria) and octanoate (a substrate for beta-
oxidation). The enhancement of glycerol-3-phosphate- and octanoate-driven respiration 
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suggests that liver mitochondria remodeled in response to alcohol feeding. In support of 
this notion, we observed that IG alcohol feeding also increased expression of 
mitochondrial glycerol phosphate dehydro- genase-2 (GPD2), transcription factor A 
(TFAM), and increased mitochondrial NAD+-NADH and NADP+- NADPH levels in the 
liver. Our findings suggest that mitochondrial dysfunction represents an incomplete 
picture of mitochondrial dynamics that occur in the liver following alcohol feeding. 
While alcohol feeding causes some mitochondrial dysfunction (i.e. succinate-driven 
respiration), our work suggests that the major consequence of alcohol feeding is 
mitochondrial remodeling in the liver as an adaptation. This mitochondrial remodeling 
may play an important role in the enhanced alcohol metabolism and other adaptations in 
the liver that develop with alcohol intake.  
 
INTRODUCTION  
Mitochondrial remodeling and biogenesis may be an important mechanism in the 
adaptation of cells to stress and metabolic changes (1). In skeletal muscle cells, chronic 
exercise has been shown to cause mitochondrial biogenesis and remodeling, involving 
a    a   a  a     -
oxidation (2 4). These mitochondrial alterations are believed to enhance mitochondrial 
respiratio  a  -oxidation to increase energy production as an adaptation to exercise. 
Metabolic changes, such as an increased fatty acid intake, have also been shown to 
a  a   a  a      a  - oxidation 
capacity (5). In another form of mitochondrial remodeling, cell starvation has been shown 
to alter mitochondrial fusion-fission to produce elongated mitochondria (6). 
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Morphological changes, such as elongation, can enhance mitochondrial respiration by 
increasing cristae surface area, and increase mitochondrial half-life by decreasing 
mitophagy. Mitochondrial remodeling, or plasticity, is therefore an important mechanism 
underlying cellular adaptation to many types of stresses and metabolic changes (1).  
We have previously shown that chronic alcohol feeding to mice resulted in 
mitochondrial remodeling involved in the adaptation of the liver to alcohol (7). 
Intragastric alcohol (IG) feeding, a method that allows for the delivery of high levels of 
alcohol, led to ~2-fold enhancement of mitochondrial respiration in mouse liver. This 
enhanced mitochondrial respiration may be due to increased expression of respiratory 
complex proteins, increased levels of mitochondrial NAD+-NADH, and possibly be due 
to alterations in mitochondrial morphology. The increased liver mitochondrial respiration 
caused by alcohol feeding was associated with increased acetaldehyde metabolism, likely 
due to enhanced NAD+ regeneration by the electron transport chain. NAD+ is the rate-
limiting substrate needed by alcohol dehydrogenase (ADH) for alcohol metabolism and 
aldehyde dehydrogenase 2 (ALDH2) for acetaldehyde metabolism (reaction 1 and 2) 
(8,9).  
 
Ethanol + NAD+ — > acetaldehyde + NADH + H+ catalyzed by ADH                    (1) 
Acetaldehyde + NAD+ +H2O— > acetate + NADH + H+ catalyzed by ALDH2      (2) 
 
Therefore, increased mitochondrial respiration may be an important adaptation to 
alcohol in the liver to enhance alcohol metabolism by increasing NAD+ regeneration. 
Oral alcohol feeding to mice (Lieber- DeCarli model), which delivers lower doses of 
alcohol, caused much less mitochondrial remodeling than IG alcohol feeding. Other 
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studies on mice that were fed alcohol orally have also observed some evidence of 
mitochondrial remodeling, including higher levels of complex I and increased 
mitochondrial respiration (10,11). Our findings appear to challenge the established 
dogma that alcoholic liver disease primarily involves mitochondrial dysfunction (12 14). 
The mitochondrial dysfunction hypothesis is primarily based on studies involving oral 
alcohol feeding to rats (Lieber-DeCarli diet), which has been shown to cause a decline in 
mitochondrial respiration (state III) and a decline in the respiratory control ratio (RCR) in 
liver mitochondria (15 17).  
The decline in mitochondrial respiration in liver was accompanied by a decline in 
ribosome activity and a decline in the synthesis of respiratory complex proteins in liver of 
rats fed alcohol orally (14,18). These findings contradict mice studies showing in- 
creased mitochondrial bioenergetics with alcohol feeding, suggesting that liver 
mitochondria in rats and mice may respond very differently to alcohol. However, a 
detailed investigation of mitochondrial changes that occur in rats with high alcohol 
feeding, which can be achieved by IG alcohol feeding (19,20), has not been performed. If 
alcohol feeding leads to mitochondrial dysfunction in rats, one would predict that 
increased alcohol delivery by IG feeding should cause a greater decline in mitochondrial 
bioenergetics in the liver.  
In humans, there is evidence that chronic alcohol use causes mitochondrial 
dysfunction in late stages of alcoholic liver disease (21). However, there is also some 
evidence of mitochondrial remodeling, with upregulation of mitochondrial enzymes, such 
as glutamate dehydrogenase in the livers of alcoholic patients (22). In this study, we 
examine the mitochondrial alterations that occur in rats fed alcohol both orally and 
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intragastrically. A complete analysis of often over- looked mitochondrial bioenergetics 
parameters, such as glycerol-3- phosphate-driven respiration, was performed in rats fed 
alcohol. The question of whether alcohol feeding in rats causes mitochondrial 
dysfunction, mitochondrial remodeling, or both is examined in this work.  
MATERIAL AND METHODS  
 
Animals  
Wistar rats (150g) were obtained from Charles Rivers (Wilmington, MA). The 
animals were housed in a temperature- controlled room and were acclimatized for a 
minimum of 3 days prior to use in experiments. All animals received care according to 
methods approved under institutional guidelines for the care and use of laboratory 
animals in research.  
Oral alcohol feeding  
Rats were fed a commercially available liquid diet (Bioserve, NJ) to which 
ethanol was mixed at 5.4% (w/v) via a feeding tube. Pair feeding was done to a control 
animal by feeding the equal amount consumed by an ethanol-fed rat except that ethanol 
was isocalorically replaced with dextrin. Rats were fed alcohol orally for 6 weeks.  
IG alcohol feeding  
IG alcohol fed rats and control rats were provided by the Southern California 
Research Center for ALPD and Cirrhosis. Rats were implanted with a long-term 
gastrostomy catheter for alcohol infusion as previously described (19). Briefly, after 1 
week of acclimatization, rats were infused with a control high fat diet with or without 
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alcohol. Alcohol infusion was initiated at a dose of 22.7 g/kg/day, and gradually 
increased. Alcohol accounted for ~ 32.9% of total caloric intake after 1 week of IG 
alcohol feeding. By 4 weeks of IG alcohol feeding, the caloric intake of alcohol 
accounted for ~38.4% of total caloric intake. Rats were fed alcohol intragastrically for 6 
weeks.  
Isolation of liver mitochondria  
Liver mitochondria from alcohol fed rats were isolated using differential 
centrifugation as previously described (23). Livers were excised, washed with 0.25 M 
sucrose and homogenized in an H- medium (210 mM mannitol, 70 mM sucrose, 2 mM 
HEPES, 0.05% bovine serum albumin (w/v), plus protease and phosphatase inhibitors). 
The homogenate was centrifuged at 850g for 10 min, the pellet (cellular debris) was 
removed, and the centrifugation process was repeated. The resulting supernatant 
(cytoplasmic fraction) was centrifuged at 8500g for 15min. The pellet, which represents 
the mitochondrial fraction, was washed with H-medium and the centrifugation was 
repeated. The mitochondria were resuspended in H- medium before oxygen electrode and 
Western blot analyses. Immunoblotting showed relatively pure fractions, as little actin 
(cytoplasmic protein) was found in the mitochondrial fraction and little glutamate 
dehydrogenase (GLUD; mitochondrial protein) was observed in the cytoplasmic fraction 
(Fig. 9).  
Measurements of respiration in isolated mitochondria  
Respiration was measured in freshly isolated mitochondria by monitoring oxygen 
consumption with a Clark-type electrode (Hansatech, UK) in respiration buffer 
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containing 230 mM mannitol, 70 mM sucrose, 30 mM Tris HCl, 5 mM KH2PO4, 1 mM 
EDTA, pH 7.4 (23). Isolated mitochondria (0.50 0.70 mg) were added to 1 ml of 
respiration buffer and oxygen consumption monitored in the presence of mitochondrial 
substrates (glutamate/malate 7.5 mM  complex I substrates; succinate 7.5 mM complex 
II a )    ADP (250 M). I   , acetaldehyde (250 
M) a   as a substrate (complex I) for mitochondrial respiration measurements. 
Mitochondrial respiration was also measured using glycerol 3-phosphate (2.5 mM), 
which feeds into glycerol phosphate dehydrogenase-2 in the mitochondrial inner 
membrane, and octanoate (200 M), a  a  a  a  a   a-
oxidation. State IV respiration is defined as respiration in the presence of substrates, 
while state III respiration is defined as respiration in the presence of both substrates and 
ADP. The RCR is defined as state III/state IV.  
Immunoblotting  
Aliquots of cytoplasmic or mitochondrial extracts were fractionated by 
electrophoresis on 8 12% SDS polyacrylamide gels (Biorad, Hercules, CA). 
Subsequently, proteins were transferred to nitrocellulose or PVDF membranes and blots 
were blocked with 5% (w/v) nonfat milk dissolved in Tris-buffered saline (TBS) with 
Tween-20. Complex I (NDUFS3 subunit), II (SDHA subunit), complex III (subunit 1), V 
(a subunit), and MCAD antibodies were obtained from Mitosciences (Eugene, OR). 
Complex IV, actin, and acetylation antibodies were obtained from Cell Signaling 
Technology (Danvers, MA). The antibody to GLUD was obtained from Santa Cruz 
(Santa Cruz, CA), the antibody to HNE was obtained from Abcam (Cambridge, MA), 
and the TFAM antibody was obtained from Avia Systems Biology (San Diego, CA). 
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Mitochondrial glycerol phosphate dehydrogenase-2 (GPD2) antibody was obtained from 
Proteintech (Chicago, Il). In rat liver mitochondria GPD2 was found primarily as a dimer 
(~ 136 kD), instead of the monomer (~68 kD). SDS treatment (4X) was used to convert a 
large percent of dimer to monomer form, but still some dimer form remained. In mouse 
mitochondria, GPD2 was primarily found in the monomer form. All blots shown are 
representative samples from 3 to 7 experiments. Densitometry was performed using the 
Image J software from NIH and normalized with appropriate loading controls.  
HPLC measurement of pyridine nucleotides  
NADP+, NADPH, NAD+, and NADH levels were measured by HPLC, as 
previously described in IG and oral alcohol fed rats (24). Briefly, liver homogenate and 
isolated mitochondria were homogenized in buffer (0.06 M KOH, 0.2 M KCN and 1 mM 
bathophenanthroline disulfonic acid) followed by chloroform extraction. Chloroform 
extraction was carried out by centrifugation at 14,000 rpm in a microcentrifuge at 4 °C; 
the resulting aqueous supernatant with soluble pyridine nucleotides was collected and 
extracted thrice to remove lipids and pr . F a ,  a    a 0.45 M 
positively charged filter (Pall Life Sciences) to remove RNA and DNA in a 
microcentrifuge at 4 °C. The mobile phase consisted of 0.2 M ammonium acetate (buffer 
A) at pH 5.5, and HPLC-grade methanol (buffer B). A gradient program with initial 
conditions as 100% buffer A and 0% buffer B was set. From 0 4 min, 0 3% B and from 
4 to 23 min, 3 6.8% B, followed by washing the column with 50% A and 50% B and re-
equilibrated to initial conditions for the next run. Quantitation of pyridine nucleotides 
was performed by integrating the peaks and adding the cyanide adducts as detected by the 
fluorescence spectrophotometer (exc=330 nm; em=460 nm).  
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Statistical analysis  
Statistical analyses were performed using the Student's t-test for unpaired data or 








































Oral and IG alcohol feeding promotes liver injury and hepatomegaly in rats  
Both oral and IG alcohol feeding significantly increased serum alanine 
aminotransferase (ALT), indicating greater liver injury, and significantly induced 
hepatomegaly (greater liver weight, liver/body weight) compared to pair fed controls 
(Table 1). However, IG alcohol feeding, which delivers greater alcohol content, caused 
significantly greater serum ALT levels (38%) than oral alcohol feeding to rats (Table 1). 
The differences in serum ALT levels between oral and IG alcohol fed rats were not as 
pronounced as differences observed in mice models, where increases in ALT levels are 
3 4 fold greater with IG alcohol feeding (7). Rats are in general believed to be more 
resistant to alcoholic liver injury (25). IG alcohol feeding also caused greater 
hepatomegaly than oral alcohol feeding to rats, as there were significant differences in 
liver weight and the liver/body weight ratio between the two alcohol models (Table 1).  
Alterations in mitochondrial state III respiration and respiratory control ratio in liver 
mitochondria from oral and IG alcohol fed rats  
Mitochondrial respiration can be assessed by introducing various respiratory 
substrates that enter the electron transport chain at different sites (Fig. 1). 
Glutamate/malate, which generates NADH that feeds into complex I, and succinate, 
which feeds into complex II, have been the most examined respiratory substrates in 
alcohol research. We observed that isolated liver mitochondria from rats fed alcohol 
orally exhibit a decline in glutamate/malate-driven and succinate-driven state III 
respiration compared to pair-fed control rats (Fig. 2A), in agreement with previous results 
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(15 17). The decline in state III respiration corresponded with a decline in the respiratory 
control ratio (RCR; state III/state IV), which was significant using glutamate/malate as 
substrates (Fig. 2B), also in agreement with previous findings (15). IG alcohol feeding to 
rats, which delivers greater amounts of alcohol and causes greater liver injury (Table 1), 
did not cause a decline in glutamate/malate-driven state III respiration (Fig. 2C), as 
observed following oral alcohol feeding. Succinate-driven respiration was reduced in 
liver mitochondria from rats fed alcohol intragastrically, though to a lesser extent than 
that in liver mitochondria from rats fed alcohol orally (IG 24%, oral 39%). IG alcohol 
feeding caused no significant declines in the RCR of isolated liver mitochondria (Fig. 
2D). These findings show that mitochondrial respiration was not worsened with greater 
alcohol dosing by IG feeding. On the contrary, oral alcohol feeding induced more 


















Figure 1. Respiratory substrates and proteins in the electron transport chain that feed electrons into 
ubiquinone. Many respiratory substrates can shuttle electrons into the four key proteins in the 
mitochondrial inner membrane that subsequently feed electrons into ubiquinone. Glutamate/malate 
treatment, through the action of various dehydrogenases such as glutamate and malate dehydrogenase, 
generates NADH that feeds into complex I. Acetaldehyde treatment also generates NADH, through the 
action of ALDH2, that also feeds into complex I. Succinate feeds into complex II (succinate 
dehydrogenase). The glycerol phosphate shuttle transfers electrons from NADH generated in the cytoplasm 
into the electron transport chain. In the glycerol phosphate shuttle, cytoplasmic glycerol phosphate 
dehydrogenase-1 (GPD1) transfers electrons from NADH to dihydroxyacetone phosphate to form glycerol-
3-phosphate (G3P). Thus, G3P then feeds electrons into the respiratory chain through the action of 
mitochondrial glycerol phosphate dehydrogenase-2 (GPD2) located in the inner membrane. Therefore, G3P 
is a respiratory substrate for GPD2. Beta-oxidation of fatty acids generates FADH2 through the action of 
various acyl-coenzyme A dehydrogenases, such as medium-chain acyl-coenzyme A dehydrogenase 
(MCAD). Electrons from FADH2 are shuttled into the respiratory chain through electron-transferring 
flavoprotein (EFT) and EFT- ubiquinone oxidoreductase. Octanoate-driven respiration, therefore, depends 






Remodeling of the respiratory complexes following oral and IG alcohol feeding to rats  
Oral alcohol feeding to rats has been shown to decrease the respiratory complexes 
(I, III, IV, and V) in liver mitochondria using blue native gel electrophoresis (BN-PAGE) 
(26). Utilizing immunoblot- ting of key respiratory complex proteins, we similarly 
observed a decline in complex I, III, IV, and V (Fig. 3A). Although immunoblotting only 
examines one subunit of the complexes, there appears to be a strong correlation between 
our immunoblotting data and published BN-PAGE data. Interestingly, complex II 
expression was not sup- pressed, even though succinate-driven respiration was the most 
inhibited by oral alcohol feeding. IG alcohol feeding, on the other hand, caused a 
significant increase in complex II levels (Fig. 3B; ~29%), even though succinate-driven 
respiration was inhibited with IG alcohol feeding to rats (Fig. 2C). IG alcohol feeding 
also caused levels of complex I and III to significantly decline, although not to the same 
extent as oral alcohol feeding (oral I - 53%, III - 46% decreased; IG I - 30%, III - 31% 
decreased). In addition, complex IV and complex V levels did not significantly change 
with IG alcohol feeding, in contrast to oral alcohol feeding. These findings demonstrate 
that oral alcohol feeding in rats suppressed the expression of respiratory complex proteins 
in liver mitochondria more extensively than IG alcohol feeding. These findings also show 
that expression of respiratory complexes and respiration do not necessarily correlate, as 
succinate- driven respiration was the most inhibited, despite its levels remaining 




Effect of chronic alcohol feeding on acetaldehyde-, glycerol-3- phosphate-, and 
octanoate-driven mitochondrial respiration in isolated liver mitochondria  
Acetaldehyde, the metabolite of alcohol metabolism generated by ADH, can act 
as a mitochondrial substrate, since ALDH2 generates NADH that feeds into complex I of 
the respiratory chain (27), similar to glutamate/malate (Fig. 1). Previous studies have 
shown that acetaldehyde metabolism is limited by the rate of NAD+ regeneration in the 
electron transport chain and thus, is coupled to mitochondrial respiration (7). It was 
therefore surprising that acetaldehyde driven-respiration was inhibited in liver 
mitochondria following oral alcohol feeding (27). In agreement with these findings, we 
observed that oral alcohol feeding to rats caused a significant decrease in state III 
respiration (~23%) in isolated liver mitochondria (Fig. 4A). IG alcohol feeding to rats, on 
the other hand, significantly increased acetaldehyde-driven respiration (~37%) in isolated 
liver mitochondria (Fig. 4A). Both oral and IG alcohol feeding did not significantly alter 
the RCR (Fig. 4B). These findings suggest that respiration through complex I (glutamate/ 
















Figure 2. Effect of oral and IG alcohol feeding on respiration through complex I and II in isolated rat liver 
mitochondria. A) State III respiration in oral alcohol fed rats. White bars=control; Dark bars=oral alcohol 
treatment. B) Respiratory control ratio (RCR) in oral alcohol fed rats. C) State III respiration in IG alcohol 
fed rats. Gray bars=control; Stripped bars=IG alcohol treatment. D) RCR in IG alcohol fed rats. State III 
respiration was measured using either complex I substrates (glutamate/malate, 7.5 mM) or complex II 
a  ( a , 7.5)  ADP (250 M)  a   . RCR   a  a  III 
respiration/state IV respiration ratio. Following 6 weeks of oral alcohol feeding or 6 weeks of IG alcohol 
feeding, liver mitochondria were isolated using differential centrifugation as described in the materials and 
methods section. N=6 8 rats per group. Results are mean +SD; * p < 0.05 versus control. Controls were fed 







We next examined mitochondrial respiration using substrates that bypass complex 
I or II. Acyl-CoA dehydrogenases are key enzymes involved in beta-oxidation that feed 
electrons into the respiratory chain through electron-transferring flavoprotein (ETF) and 
ETF-ubiquinone oxidoreductase (Fig. 1). We examined mitochondrial respiration 
utilizing octanoate, a medium chain fatty acid, that undergoes beta-oxidation in 
mitochondria through the action of medium-chain acyl-coen- zyme A dehydrogenase 
(MCAD). Octanoate-driven respiration was significantly increased in isolated liver 
mitochondria from both oral and IG alcohol fed rats (~33% for both; Fig. 4C). The 
glycerol phosphate shuttle transfers electrons from NADH generated in the cytoplasm 
into the electron transport chain.  
In the glycerol phosphate shuttle, cytoplasmic glycerol phosphate dehydrogenase-
1 (GPD1) transfers electrons from NADH to dihydroxyacetone phosphate to form 
glycerol-3-phosphate (G3P), which then shuttles electrons into the respiratory chain 
through the action of mitochondrial glycerol phosphate dehydrogenase-2 (GPD2) located 
in the inner membrane (28). Thus, G3P is a respiratory substrate for GPD2 (Fig. 1). As 
observed with octanoate, G3P-driven respiration was significantly enhanced in isolated 
liver mitochondria from both oral and IG alcohol fed rats (~26% oral; ~41% IG; Fig. 4C). 
Utilizing octanoate and G3P, we observed for the first time that mitochondrial state III 
respiration can increase in the liver following oral alcohol feeding to rats. Changes in 
RCR were not statistically significant for both octanoate- and G3P- driven respiration, 









Figure 3. Alcohol feeding alters protein levels of respiratory complexes in the electron transport chain of 
rat liver mitochondria. A) Oral alcohol fed rats. White bars=control; Dark bars=oral alcohol treatment. B) 
IG alcohol fed rats. Gray bars=control; Stripped bars=IG alcohol treatment. Following 6 weeks of oral 
alcohol feeding or 6 weeks of IG alcohol feeding, mitochondria were isolated using differential 
centrifugation, and protein levels were assessed by immunoblotting. Integrated (Int) densitometry was 
performed using Image J. Glutamate dehydrogenase (GLUD) was used as the loading control after it was 
observed not to change with alcohol feeding. AU=arbitrary units. Com=complex. N=6 8 rats per group. 








Remodeling of the mitochondrial proteins following oral and IG alcohol feeding to rats  
We next examined protein levels by immunoblot analysis of key proteins 
involved in mitochondrial respiration driven by the respiratory substrates examined in 
Fig. 4. Protein levels of ALDH2 and MCAD, which are important in shuttling electrons 
from acetaldehyde and octanoate, respectively, were not significantly altered with oral or 
IG alcohol feeding (Fig. 5A and B). Protein levels of GPD2, on the other hand, were 
increased significantly in liver mitochondria from rats fed alcohol intragastrically (~33%; 
Fig. 5B). Oral alcohol feeding did not cause a significant increase in GPD2 protein levels, 
although G3P- driven respiration was increased. GPD2 was expressed in rat liver 
mitochondria as both a dimer and a monomer, while in mice it was mainly seen in its 
monomeric form (Fig. 6C). Both oral and IG alcohol feeding to rats also enhanced 
expression of mitochondrial transcription factor A (TFAM), a key transcription factor 
(nuclear gene) that is important for transcribing genes from mtDNA (29) (Fig. 5). 
Increased TFAM expression suggests that transcription in mitochondria may increase 
with alcohol feeding. Overall, the fact that alcohol feeding, particularly IG alcohol 
feeding, caused an increase in several respiratory proteins suggests that mitochondrial 

















Figure 4. Effect of oral and IG alcohol feeding on acetaldehyde-, G3P-, and octanoate-driven respiration in 
isolated rat liver mitochondria. A) Acetaldehyde-driven state III respiration. White bars=oral control, Dark 
bars=oral alcohol treatment; Gray bars=IG control; Striped bars=IG alcohol treatment. B) RCR using 
acetaldehyde as substrate. C) G3P-and octanoate-driven state III respiration. D) RCR using G3P and 
a a  a  a . S a  III a  a  a    a a  (180 M), G3P (2.5 
M),  a a  (200 M)  ADP (250 M)  a   . F  6  f oral 
alcohol feeding or 6 weeks of IG alcohol feeding, liver mitochondria were isolated using differential 


























Figure 5. Effect of alcohol feeding on expression of mitochondrial proteins in the liver of rats A) Oral 
alcohol fed rats. White bars=control; Dark bars=oral alcohol. B) IG alcohol fed rats. Gray bars=control; 
Striped bars=IG alcohol. Following 6 weeks of oral alcohol feeding or 6 weeks of IG alcohol feeding, 
mitochondria were isolated using differential centrifugation, and mitochondrial protein levels were assessed 
by immunoblotting. Integrated (Int) densitometry was performed using Image J. Glutamate dehydrogenase 
(GLUD) was used as the loading control. ALDH2 - aldehyde dehydrogenase 2; MCAD - medium-chain 
acyl-coenzyme A dehydrogenase; GPD2 - mitochondrial glycerol phosphate dehydrogenase-2, TFAM - 







Enhanced beta-oxidation and G3P-driven respiration also occurs in mice fed alcohol 
intragastrically  
Since GPD2 plays a key role in transferring electrons generated by ADH in the 
cytoplasm to mitochondria, we explored whether this pathway was also enhanced in mice 
fed alcohol intragastrically. In mice, both octanoate- and G3P-driven respiration was 
enhanced by alcohol feeding (Fig. 6A). As observed in rats, no statistically significant 
changes in RCR were observed, although in all case RCR tended to decline (Fig. 6B). 
Protein levels of both MCAD and GPD2 were increased with IG alcohol feeding in mice 
(Fig. 6C). GPD2 in mice was seen primarily as a monomer, unlike in rats where it is was 
mainly observed as a dimer. These findings suggest that up-regulation of GPD2 in liver 
mitochondria may be a key adaptation to chronic alcohol feeding in both mice and rats.  
Effect of alcohol feeding on NAD+-NADH levels and redox status in isolated liver 
mitochondria  
Because NAD+ is the rate limiting substrate in alcohol metabolism, NAD+-
NADH levels and redox status were examined in isolated liver mitochondria following 
oral and IG alcohol feeding to rats. In mice, we previously observed that both oral and IG 
alcohol feeding increased total NAD+-NADH levels in liver mitochondria (7). In rats, a 
similar pattern was observed, as both oral and IG alcohol feeding significantly increased 
the total NAD+-NADH levels in liver mitochondria (oral - 27%, IG - 48%; Fig. 7). Since 
alcohol metabolism depends on NADH shuttling to regenerate NAD+, an increase in the 
NAD+-NADH pool in liver mitochondria could potentially enhance alcohol metabolism 
through increased NADH cycling (7). The major difference observed between oral and 
IG alcohol fed rats was the NADH/NAD+ ratio (Fig. 7). In oral alcohol fed rats, 
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mitochondria had a significantly greater NADH/NAD+ ratio, suggesting a possible 
buildup of NADH from increased ADH activity and inhibition of respiration through 
complex I. IG alcohol feeding, which is associated with greater alcohol intake but 
enhanced respiration through complex I, resulted in the NADH/NAD+ ratio being similar 
to control.  
 
Effect of alcohol feeding on NADP+-NADPH levels and redox status in isolated liver 
mitochondria  
NADPH plays an important role in biosynthesis, redox status, and alcohol 
metabolism (cytochrome P450-dependent metabolism) in cells and mitochondria (30). 
Oral alcohol feeding was found to significantly increase NADP+, NADPH, and total 
NADP+-NADPH levels in liver mitochondria, while IG alcohol feeding was found to 
significantly increase NADPH, and total NADP+-NADPH levels in liver mitochondria 
(Fig. 8). Alcohol feeding did not significantly affect the NADPH/ NADP+ ratio in 
mitochondria, which generally favors the reduced form. An enhancement of 
mitochondrial NADPH by alcohol feeding may be an important adaptation to oxidative 













Figure 6. Enhanced G3P-, and octanoate-driven respiration is also observed in murine liver mitochondria 
following IG alcohol feeding. A) G3P and octanoate-driven state III respiration in isolated liver 
mitochondria from mice. Empty bars=control mice; Vertical striped=IG mice B) RCR using G3P and 
octanoate as substrates. C) Effect of IG alcohol feeding on MCAD and GPD2 expression in isolated mice 
 a. S a  III a  a  a    G3P (2.5 M),  a a  (200 M) 
 ADP (250 M)  a   . F  5   IG a  feeding, liver mitochondria 
were isolated using differential centrifugation. Complex III (com III) was used as the loading control, since 
we previously observed that it does not change in mice with alcohol feeding. N=7 8 mice per group. 














Figure 7. Effects of oral and IG alcohol feeding on NAD+ -NADH levels and redox status in liver 
mitochondria. A) Oral alcohol fed rats. White bars=control; Dark bars=oral alcohol treatment. B) IG 
alcohol fed rats. Gray bars=control; Striped=IG alcohol treatment. Following 6 weeks of oral alcohol 
feeding or 6 weeks of IG alcohol feeding, mitochondria isolated using differential centrifugation. NAD+ 
and NADH levels were measured by HPLC with a fluorescence detector. N=5 6 rats per group. Results are 











Effect of oral and IG alcohol feeding on oxidative damage and N- acetylation in rat liver  
We next examined the differences in post-translational protein modifications that 
oral and IG alcohol feeding caused in rats. Previously, we demonstrated that N-
acetylation of proteins (lysine residues) in isolated mitochondria was increased with both 
oral and IG alcohol feeding to mice (7). In rats, both oral and IG alcohol feeding 
significantly increased N-acetylation in mitochondrial proteins com- pared to their 
respective controls (Fig. 9A, C). N-acetylation induced by alcohol feeding occurred 
primarily in mitochondrial proteins (25  150 kD range), suggesting preferential targeting. 
N-acetylation appears to increase equally with both oral and IG alcohol feeding in rats, in 
contrast to mice where N-acetylation was greater with IG feeding. Oral fed control rats 
had greater N-acetylation in the liver than IG controls, suggesting that feeding models 
influence N-acetylation irrespective of alcohol. The levels of N-acetylation in IG controls 
were similar to untreated rats (ad-libitum; data not shown), suggesting dietary changes 
associated with oral feeding enhances N-acetylation in liver mitochondria.  
We also measured 4-hydroxynonenal (HNE)-protein adducts in the liver to assess 
oxidative stress induced by alcohol. HNE-protein adducts increase with lipid 
peroxidation, as HNE is formed by the breakdown of lipid peroxides. Only one consistent 
HNE-protein adduct (~250 kD) was observed in the liver, and only in the cytoplasmic 
fraction (Fig. 9A-B). IG alcohol feeding, but not oral alcohol feeding, significantly 
increased formation of this HNE-adduct, supporting the idea that increased alcohol 











Figure 8. Alcohol feeding to rats increases mitochondrial NADP+ -NADPH levels in the liver. A) Oral 
alcohol fed rats. White bars=control; Dark bars=oral alcohol treatment. B) IG alcohol fed rats. Gray 
bars=control; Stripped bars=IG alcohol treatment. Following 6 weeks of oral alcohol feeding or 6 weeks of 
IG alcohol feeding, mitochondria were isolated using differential centrifugation. NADP+ and NADPH 
levels were measured by HPLC with a fluorescence detector. N=5 7 rats per group. Results are mean+SD; 










Previous studies that have examined the effect of alcohol feeding on 
mitochondrial changes in the liver have mainly utilized the oral alcohol model in rats 
(15,16). Oral alcohol feeding to rats had been shown to cause significant declines in 
mitochondrial state III respiration, decreased expression of respiratory complex proteins, 
and declines in RCR, all of which were also observed in this study. These findings, along 
with other studies demonstrating other types of mitochondrial damage (i.e. mtDNA 
oxidation, post-translational modification, oxidative stress) have led to the widely 
a   a  a    a   a   a  
(12,13). Our previous findings that alcohol feeding in mice causes mitochondrial 
remodeling and enhances mitochondrial respiration in liver mitochondria seem to 
contradict the mitochondrial dysfunction hypothesis based primarily on the oral alcohol 
rat model (7). In this study, our comparison of oral versus IG feeding models in rats 
demonstrated that no relationship between mitochondrial dysfunction and alcohol dosing 
occurs. IG alcohol feeding to rats did cause greater oxidative stress (HNE-protein 
adducts), but also caused less mitochondrial dysfunction (i.e. succinate driven-
respiration), and greater mitochondrial remodeling (i.e. increased acetaldehyde-, 
octonoate-, GP3-  a ). T ,   a   a  
 a a   a     a  a a  a  
occur in the liver with alcohol feeding. While alcohol feeding causes some mitochondrial 
dysfunction and injury (i.e. succinate-driven respiration), our work suggests that the 
major consequence is mitochondrial remodeling in the liver as an adaptation to the stress 








Figure 9. Effect of oral and IG alcohol feeding on oxidative damage and N-acetylation in cytoplasmic and 
mitochondrial fractions of rat liver. A) Following 6 weeks of oral alcohol feeding or 6 weeks of IG alcohol 
feeding, mitochondrial and cytoplasmic (soluble fraction minus mitochondria) fractions were isolated using 
differential centrifugation. Levels of HNE-protein protein adducts and N-acetylation (lysine) were assessed 
by immunoblotting. Densitometry was performed using Image J. Glutamate dehydrogenase (GLUD) was 
used as the mitochondrial loading control. Actin was used as the cytoplasmic loading control. Mit = 
mitochondrial fraction. Cyt = cytoplasmic fraction. Results are mean+SD; * p < 0.05 versus IG control. ** 








Effect of alcohol feeding on mitochondrial respiration  
It is clear that feeding alcohol orally to rats causes a decline in many important 
bioenergetic parameters, including a decline in glutamate/ malate- and succinate-driven 
respiration in liver mitochondria. These declines in mitochondrial respiration following 
oral alcohol feeding have generally been attributed to decreased expression of complexes 
I, III, IV, and V in liver mitochondria. However, mitochondrial respiration and levels of 
respiratory complex proteins do not seem to necessarily correlate in rats, as there is no 
decline in expression of complex II even though succinate-driven respiration is the most 
inhibited with alcohol feeding. Although declines in respiratory com- plex proteins and 
mitochondrial respiration can imply dysfunction, these changes may also be indicative of 
mitochondrial remodeling. Alcohol feeding is associated with excess or sufficient energy 
intake, and therefore, it is possible that the liver may be downregulating components of 
the electron transport chain as a response to excess energy levels from alcohol intake. It 
may also be that complex I respiration is downregulated, so that other respiratory 
pathways including GPD2 and beta-oxidation are enhanced.  
Since NADH generated in the cytoplasm by ADH cannot cross the mitochondrial 
inner membrane, GPD2 is an important pathway in shuttling electrons from cytoplasmic 
NADH into mitochondria to regenerate NAD+ for alcohol metabolism (30). The 
enhanced G3P- and octanoate-driven respiration may be particularly useful adaptations to 
alcohol feeding, since enhanced GPD2 may increase alcohol metabolism by ADH and 
enhanced beta-oxidation may help reduce fatty liver. Enhancement of octanoate-driven 
and G3P-driven respiration was also observed in the liver of mice fed alcohol 
intragastrically, suggesting that upregulation of these pathways are major adaptations to 
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alcohol. Taken together, our work suggests that a significant number of mitochondrial 
alterations following alcohol feeding were due to mitochondrial remodeling, rather 
mitochondrial dysfunction.  
One mitochondrial alteration in liver mitochondria that strongly supports 
mitochondrial dysfunction due to alcohol feeding was the decline in succinate-driven 
respiration. Both oral and IG alcohol feeding significantly decreased succinate-driven 
respiration, even though levels of complex II were unchanged (oral) or significantly 
increased (IG). Increased levels of complex II following IG alcohol feeding suggests that 
increased synthesis of complex II protein levels was compensating for an inhibition of 
complex II. Complex II may be inhibited by post-translational modifications to 
mitochondrial proteins, such as nitrosylation and N-acetylation, that have been shown to 
increase with alcohol feeding (31 33). Our work shows that N- acetylation is increased 
with both oral and IG alcohol feeding, suggesting this protein post-translational 
modification may play a role in the decline in complex II activities that occurs with 
alcohol feeding. Interestingly, we observed that N-acetylation occurred equally with oral 
and IG alcohol feeding, which requires further investigation. The targeting of N-
acetylation to mitochondrial proteins and its mechanism of induction by alcohol feeding 
requires further investigation. Complex II has also been shown to be inhibited by 
oxidative stress through an oxaloacetate dependent pathway (34). Further research is 
needed to understand the mechanism by which succinate-driven respiration is inhibited 
by oral and IG alcohol feeding in rats. In mice, succinate- driven respiration is enhanced 




Effect of alcohol feeding on acetaldehyde-driven respiration  
An important observation that led to the mitochondrial dysfunction hypothesis has 
been the observed decline in acetaldehyde-driven respiration in liver mitochondria 
following oral alcohol feedings to rats. Indeed, it is puzzling that metabolism of a key 
toxicity inter- mediate of alcohol metabolism would decline with alcohol feeding. 
However, we observed that the higher alcohol delivery associated with IG alcohol 
feeding enhanced acetaldehyde-driven respiration in liver mitochondria. This implies that 
at a higher alcohol dose, which generates higher levels of acetaldehyde, liver 
mitochondria adapt and metabolize acetaldehyde at a greater rate. Acetaldehyde 
respiration and metabolism measurements are usually performed using high micro- molar 
concentrations of acetaldehyde. It may be that oral alcohol feeding does not generate high 
enough levels of acetaldehyde in the liver to sufficiently decrease its metabolism even 
when complex I expression is suppressed. It was surprising that IG alcohol feeding 
enhanced acetaldehyde-driven respiration considering that protein levels of complexes I 
and III declined in liver mitochondria. However, mitochondria in rats have been shown to 
have excess respiratory complex proteins (35) and mitochondria tend to exhibit a 
a    (36).  
It has been estimated that up to 70% of complexes III and IV may be reduced 
before mitochondrial respiration is inhibited in rat brain and muscle mitochondria (35). 
Thus, it is possible that acetaldehyde driven-respiration is enhanced even when 
expression of respiratory complexes are suppressed due to increased substrate transport 
into mitochondria, changes in Fe-S cluster levels in the respiratory complexes, formation 
of supercomplexes, increased ALDH2 activity, or increased levels of pyridine 
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nucleotides. In addition, although our immunoblotting data correlates well with 
previously published BN-PAGE data, by measuring only key subunits of the respiratory 
complexes, we may be missing protein alterations in the complexes that may help 
enhance acetaldehyde- driven respiration. Overall, the excess respiratory proteins 
observed in rat mitochondria may help explain why changes in respiratory complex 
protein levels often did not correlate with changes in mitochondrial respiration following 
alcohol feeding to rats. In mice, there are much stronger correlations between changes in 
mitochondrial respiration and changes in respiratory complex levels in the liver following 
alcohol feeding. Further research is needed to characterize the mitochondrial threshold 




Decline in RCR in liver mitochondria caused by alcohol feeding  
In all respiratory substrates examined there was a trend for a decline in RCR, with 
the decline being statistically significant with succinate in IG alcohol fed rats, and 
glutamate/malate for oral alcohol fed rats. A decline in RCR suggests that mitochondria 
are more uncoupled and have reduced ATP production capacity. Since mitochondria can 
become uncoupled following mitochondrial injury or damage, it is often a sign of 
mitochondrial dysfunction. However, uncoupling of mitochondria also has physiological 
functions. Mitochondrial uncoupling can be induced and regulated by the family of 
uncoupling proteins (UCP) (37). The physiological functions of mitochondrial 
uncoupling include generation of heat and decreased mitochondrial ROS generation due 
to the shorter half-life of the ubisemiquinone radical responsible for ROS generation 
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(38,39). Since alcohol feeding causes excess energy and leads to increased fatty acid 
formation, ATP levels are not limiting in the liver. Thus, under conditions of excess 
energy, uncoupled mitochondria may be a form of adaptation to quickly regenerate 
NAD+ needed for alcohol metabolism, without generating excess ATP and generating 
less ROS. Further research is needed to determine if declines in mitochondrial RCR 
caused by alcohol are due to mitochondrial damage, or an adaptation possibly involving 
UCP.  
 
Increased levels of pyridine nucleotides in liver mitochondria  
Both oral and IG alcohol feeding to rats increased the NAD+-NADH pool and 
NADP+-NADPH pool in liver mitochondria. Since alcohol and acetaldehyde metabolism 
depends on NADH shuttling to regenerate NAD+, an increase in the NAD+-NADH pool 
in liver mitochondria could potentially contribute to enhanced NADH cycling and 
alcohol metabolism. Increased levels of mitochondrial NAD+-NADH could also 
potentially be contributing to enhanced acetaldehyde-driven respiration observed with IG 
alcohol fed rats despite decreased expression of complexes I and III in liver 
mitochondria. Another interesting observation seen in this work was that oral alcohol 
feeding increased the NADH/NAD+ ratio in liver mitochondria, suggesting a buildup of 
NADH from alcohol metabolism. It is possible that the decreased respiration through 
complex I may be contributing to a buildup of NADH in oral alcohol fed rats. With oral 
alcohol feeding, there seems to be an inability to achieve the normal NADH/NAD+ ratio, 
suggesting mitochondrial stress. However, with IG feeding, liver mitochondria seem to 
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adapt, with complex I respiration being greater than control (acetaldehyde-driven 
respiration), causing the NADH/NAD+ ratio to increase only slightly above basal levels.  
NADPH plays an important role in biosynthesis and in maintaining the redox 
status in cells and mitochondria (30,40). Consequently, it is not surprising that both oral 
and IG alcohol feeding enhanced NADPH and total NADP+-NADPH levels in liver 
mitochondria. Alcohol feeding is known to generate oxidative stress and alter the redox 
status of proteins in mitochondria (41), and increased NADPH levels are likely an 
adaptive response. NADPH is also the key substrate for cytochrome P450s, such as 
CYP2E1, that help metabolize alcohol and are upregulated with alcohol feeding. The 
effect of alcohol intake on pathways, such as mitochondrial nicotinamide mononucleotide 
adenylyltransferase (NMNAT-3) and NAD+ kinase (NADK) that synthesizes NADPH 
needs to be further explored (30). Overall, the increased levels of pyridine nucleotides in 
liver mitochondria may be an important adaptive mechanism to help with alcohol 
metabolism and alcohol detoxification.  
 
Model of mitochondrial remodeling  
Alcohol feeding clearly causes some mitochondrial dysfunction in rats, such as a 
decline in succinate-driven respiration. Alcohol feeding has also been shown to increase 
mitophagy in the liver to remove damaged mitochondria (42). While mitochondrial 
dysfunction is im- portant in alcoholic liver disease, it represents an incomplete picture of 
mitochondrial dynamics that occur in the liver following alcohol feeding. Our data 
suggests that mitochondria also adapt and undergo dynamic alterations with chronic 
alcohol feeding. In mice, we see dramatic mitochondrial remodeling that enhances 
mitochondrial re- spiration over 2-fold. In rats, the mitochondrial remodeling is not as 
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dramatic, but we do observe increases in pyridine nucleotide levels and increased G3P-, 
octanoate-, and acetaldehyde-driven respiration (IG only). Thus, we are proposing a 
model in which alcohol feeding generates stress and mitochondrial injury. Following this 
stress and injury, mitochondria remodel to adapt to the stress of alcohol feeding. 
Mitochondrial remodeling in the liver varies depending on the dose of alcohol intake (the 
greater the alcohol content the greater the remodel- ing) and between species (rats and 
mice). Mitochondrial remodeling is therefore likely to be highly variable in a 
heterozygous human population, depending on the genetic composition of patients and 
doses of alcohol consumed. It may be that some mitochondrial alterations have greater 
pathological consequences that promote liver injury through mechanisms such as 
increased ROS generation. G3P-driven respiration has been shown to have higher ROS 
generation than other respiratory pathways (43). In support of this notion, ROS 
generation appears to increase with IG alcohol feeding, as evidenced by the fact that 
HNE- protein adduct formation in the liver increased with IG feeding.  
However, since alcohol metabolism by cytochrome P450 and other pathways can 
also increase ROS generation, further work is needed to determine the contribution that 
mitochondrial remodeling is making to the increased ROS generation observed with IG 
alcohol feeding. Mitochondrial remodeling could also potentially be involved in the 
increased sensitivity of liver mitochondria to mitochondrial permeability transition 
(MPT) that is observed with oral alcohol feeding (44). Therefore, mitochondrial 
remodeling may help the liver adapt to alcohol in the short-term, but long-term may 
contribute to liver injury, which needs to be further explored.  
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In many ways, chronic alcohol feeding is analogous to exercising the liver. 
Exercise in muscle is associated with significant mitochondrial remodeling as an 
adaptation (2). Exercise is also a stress in muscles and is associated with increased ROS 
(45). Alcohol can be seen as exercising the liver by stressing the metabolic pathways of 
the liver and promoting ROS generation to trigger mitochondrial remodeling. It has been 
well established that the liver adapts to alcohol feeding, and rapidly develops an 
enhanced capacity to metabolize alcohol (46). Mitochondrial remodeling may play an 
important role in enhanced alcohol metabolism and other adaptations that the liver 
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CHAPTER 3:  
DOXORUBICIN-INDUCED MITOCHONDRIAL REMODELING AND DRUG 





Mitochondria oscillate along a morphological continuum from fragmented 
individual units to hyperfused tubular networks. Their position at the junction of 
catabolic and anabolic metabolism couples this morphological plasticity, called 
mitochondrial dynamics, to larger cellular metabolic programs, which in turn implicate 
mitochondria in a number of disease states. In many cancers, fragmented mitochondria 
engage the cell with the biosynthetic capacity of aerobic glycolysis in service of 
proliferation and progression. Chemo-resistant cancers, however, favor remodeling 
dynamics that yield fused mitochondrial assemblies utilizing oxidative phosphorylation 
(OXPHOS) through the electron transport chain (ETC). In this study, expression of 
Mitofusin-2 (MFN-2), a GTPase protein mediator of mitochondrial fusion, was found to 
closely correlate to Jurkat leukemia cell survival post doxorubicin (DxR) assault. 
Moreover, this was accompanied by dramatically increased expression of OXPHOS 
respiratory complexes and ATP Synthase, as well as a commensurate escalation of state 
III respiration and respiratory control ratio (RCR). Importantly, CRISPR knockout of 
MFN-2 resulted in a considerable decrease of DxR median lethal dose compared to a 
treated wildtype control, suggesting an important role of mitochondrial fusion in 







T-cell leukemias are a group of blood cancers that are among the most common in 
the world, affecting over 2.3 million people globally and causing 353,000 deaths annually 
(1,2). Notably, leukemia is the most common pediatric cancer (3). Standard of care 
treatments routinely incorporate the CHOP (cyclophosphamide, hydroxydaunorubicin, 
oncovin, prednisone) chemotherapy regimen (4), which includes the intercalating 
anthracycline doxorubicin (DxR). While useful in treating early- to mid-stage lymphomas 
(5), sustained DxR-inclusive CHOP also presents significant side effects to patients, 
including dilated cardiomyopathy, congestive heart failure, and death. Moreover, 
cancerous cells exposed to repeated dosing of chemotherapy regimens, as well as those 
that are recurrent, are frequently less primed to undergo mitochondria-mediated intrinsic 
apoptosis(6), making them less sensitive to additional applications of chemotherapy. This 
is significant, as lymphoblastic leukemias have a relapse rate of 10- 25% in children 
(7,8), for which prognoses are dramatically impacted (9).  As such, mitochondrial action 
in leukemia cells under chemotherapeutic assault serves as a potentially crucial area in 
which to research drug sensitivity and efficacy.  
Mitochondria are active, double-membrane bound hubs of bioenergetics, cell 
signaling, and redox balance that fluctuate along a spectrum of fused superstructures to 
smaller, fissed organelles. Importantly, these morphological changes- together called 
mitochondrial dynamics- are closely connected to larger metabolic schemes. Specifically, 
fission has been shown to favor glycolysis (10), while several studies have linked fusion 
with induction of oxidative phosphorylation/OXPHOS (11,12,13,14), and are mediated 
by the action of a family of intracellular GTPase proteins. For example, the GTPase 
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dynamin related protein (DRP-1), when phosphorylated at serine616, localizes with 
Mitochondrial Fission Factor (Mff) at the outer mitochondrial membrane (OMM), 
dividing targeted mitochondria at scission sites to induce a fragmented network 
morphology and a switch to glycolytic metabolism. Conversely, the mitofusin proteins 
(MFN-1,2) function to merge the mitochondrial outer membrane (MOM) of fusing 
mitochondria. The relative balance of these proteins and their subsequent action are 
essential to normal cell physiology, and their dysregulation has been connected to a 
number of cancers (15). Conversely, mitochondrial fusion has been shown to inhibit 
migration in breast cancer, establishing a linking mechanism between cancer 
invasiveness and mitochondrial dynamics (16). Unfortunately, many similar links 
between mitochondrial dynamics and cell sensitivity to chemotherapy remain unexplored 
or poorly characterized.  
The present study aimed to address this dearth by examining the effects of 
doxorubicin on the mitochondrial dynamics in leukemia Jurkat cells, with particular 
attention paid to mitochondrial phenotype and respiratory capacity in cells surviving 
chemotherapeutic assault. We also sought to characterize the relationship between those 
mitochondrial dynamics and cellular sensitivity to DxR. Our subsequent data show that 
both MFN-2 and OXPHOS respiratory complexes are significantly upregulated in 
surviving leukemia cells, and that MFN-2 knockout substantially increases Jurkat 
sensitivity to DxR, providing a potential target for increasing chemotherapy efficacy and 





MATERIALS AND METHODS 
 
 
Cell culture and chemotherapy application 
 
Jurkat peripheral blood t-lymphocytes were grown in RPMI medium 
supplemented with 2mm glutamine, 10% fetal bovine serum, and penicillin/ streptomycin 
(50 M·mL 1), all from ThermoFisher/Gibco (Waltham, Massachusetts), in a humidified 




Suspension was spun down at 900 RPM to separate live cells. For trypan 
exclusion, a 0.4% trypan solution (SigmaAldrich, St. Louis, Missouri) was applied to 
fresh cell suspension in a 1:1 ratio. Flow cytometry was performed per the protocol in 
prior studies (17).  
 
Mfn-2 knockout CRISPR vector transfection  
 
Mfn2 CRISPR/Cas9 KO Plasmid was obtained from Santa Cruz Biotechnology 
(Santa Cruz, California), mixed in proportion with SCBT UltraCruz Transfection Reagent 
(Santa Cruz, California) and OPTI-MEM Reduced Serum Media (ThermoFisher, 
Walthham, Massachusetts), and applied to cells in-vitro for 72 hours, mixing suspension 








Western blot was conducted as per our previous work (18). Total OXPHOS 
cocktail, DRP-1, pDRP-1, and MFN-2 primary antibodies were obtained from Abcam 
(Cambridge, UK).  
 
Real-time quantitative PCR  
 
RT-qPCR was performed via our previous work (19), using forward and reverse 
primers for the following human genes: MFN-2, DRP-1, and an 18S internal control. 
 
Mitochondrial respiration measurements 
 
Respiration was measured in freshly cultured control and treated Jurkats 
according to our previously described procedures (20).  
 
Statistical Analysis  
 
Statistical analyses were performed using the Student's t-test for unpaired data. P 






DxR cytotoxicity  
 
Titration of 24-hour doxorubicin treatments established the median lethal dose for 
a Jurkat t-cell culture. A trypan exclusion assay and statistical analysis showed 
cytotoxicity in a dose-dependent relationship. 0.75 M DxR was found to reduce cell 
viability by approximately half (53% of control, ± 6.6), with 0.5 M and 1.0 M 
respectively constituting low (65% of control, ± 5.3 reduction) and high (38% of control, 
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± 11.3 reduction) dosing states (FIGURE 1A). For validation, cell cycle analysis using 
0.75 M DxR corroborated its median dose cytotoxicity, increasing the DNA 
fragmentation subpopulation (indicative of apoptosis) of treated Jurkats to 52.3% ± 6.4, 
while reducing the proportion of cells in the proliferative G2/M phase to 4.5% ± 0.9, 
















































Figure 1. A) Doxorubicin (DxR) cytotoxicity for suspended jukrat t-cell cultures over a treatment interval 
of 24 hours determined through trypan exclusion. Viable population  is reduced dose-dependently with 
increases to DxR treatment concentration, with approximate acute median lethal dose (LD50) achieved at 
0.75 M (53% of untreated control, ± 6.6%). B) Cell cycle phase analysis via flow cytometry. Fragmented 
DNA is used as indication of apoptosis, given DNA intercalation mechanism of DxR. DxR treatment at 
0.75 M increases DNA fragmented cell proportion from 15.8% ± 3.0% of population to 52.3% ± 6.4% 
versus untreated control. Additionally, the proportion of proliferative G2/M phase in treated cells is 4.5% ± 
















DxR induces changes to mitochondrial remodeling, including MFN-2 mediated 
mitochondrial fusion  
 
Versus control, DxR treatment across low (0.25 M), medium (0.50 M), and high 
(1.0 M) concentrations induced rapid transcription of fusion mediating MFN-2 
beginning at 1hr and continuing through 24-hours (FIGURE 2B). Western immunoblot 
revealed expression of MFN-2 was greatly increased for all treated groups versus control. 
Interestingly, protein expression of Mitofusin-1 (MFN-1), a homolog of MFN-2, only 
marginally increased. The pleiotropic protein Prohibtin-1 (PHB-1), which forms ring 
structures at the mitochondria inner membrane to support fusion morphology and 
OXPHOS, increased with DxR concentration, suggesting inner membrane fusion 
maintenance.  Conversely, production of DRP-1, both in its total pool and activated 
phosphorylated (serine616) forms, was found to be inversely correlated to DxR 
concentration beginning at the 1-hour timepoint (FIGURE 2B), indicating suppression of 
mitochondrial fission. 
 
Oxidative phosphorylation, respiration rate, and mitochondrial coupling are upregulated 
and enhanced in cells that survive DxR assault  
 
Mitochondrial fusion is associated with energy production via electron transport 
and oxidative phosphorylation (OXPHOS). To assess if our observation of upregulated 
MFN-2, along with its mediated fusion, predicated subsequent increases in OXPHOS 
activity, we probed for subunits of each respiratory chain complex, I-V (FIGURE 2C). 
Significant increases were observed for complexes I, III, and IV, with a substantial 10-
fold surge occurring for complex V, ATP Synthase. Interestingly, expression for complex 










Figure 2. A) Real-time quantitative PCR gene detection comparison measuring protein mediators of 
mitochondrial morphology across DxR treatment concentrations at 1 and 24 hours relative to an 18s control 
gene. At 1 hour post-DxR treatment, transcript of DRP-1, a GTPase mediator of mitochondrial fission, is 
shown to decrease. This is accompanied by a concurrent increase of MFN-2, a mitochondrial outer 
membrane fusion mediator, indicating hasty mitochondrial fusion in response to DxR; these same dynamics 
are observed at a 24 hour endpoint. B) Immunoblot of mitochondrial dynamics mediators in DxR treated t-
cells at 24 hours. Corroborating RT-qPCR data, both DRP-1 and activated pDRP-1s616 are decreased in 
response to treatment. MFN-2 is likewise shown to increase as in RT-qPCR assay, though an increase of 
MFN-1 was determined to be statistically insignificant. PHB-1, a pleiotropic scaffolding protein known to 
stabilize mitochondrial inner membrane proteins and support cristae morphogenesis and maintenance, is 
upregulated in treated conditions compared to control. Taken together, data suggest MFN-2 mediated 
fusion in response to DxR, beginning at the latest 1 hour after treatment, through to a 24 hour interval. Data 











 To determine if the upregulation of mitochondrial fusion and OXPHOS complexes in 
treated cells accompanied respiration rate changes, we introduced a glutamate/malate 
respiratory substrate to facilitate electron entry into the ETC via Complex I. Using ADP 
+ glutamate/malate-generated NADH, which facilitates shuttling electrons to Complex I, 
we observed that mitochondria in treated cells increase state III respiration compared to 
control (FIGURE 3A). This corresponded with lower state IV respiration and an 
escalation in the respiratory control ratio (RCR; state III/state IV), indicating increased 
mitochondrial coupling and more efficient ATP production (FIGURE 3B).  
 
MFN-2 significantly increases chemoresistance and insensitivity  
 
 
 To deduce the role of MFN-2 in the DxR drug response of Jurkats, we next knocked out 
its expression through transfection of an MFN-2 KO CRISPR vector. Knockout was 
validated through western immunoblot (FIGURE 4A). To ensure that there was no 
compensatory MFN-1 expression to induce unaccounted fusion, we probed for it again, 
finding little change (data not shown). DxR was administered at 0.50 M, 0.75 M, and 
1.0 M to both wildtype control and MFN-2 knockout cultures for a duration of 24 hours. 
Compared to control, median lethal dose for MFN-2-KO was reduced from 0.81 M in 













Figure 3. A) Immunoblot of electron transport chain respiratory proteins. Compared to untreated control, 
complexes I, III, and IV are greatly upregulated, with the largest increase in expression occurring in 
complex V (ATP Synthase), indicating increased ATP production via oxidative phosphorylation. 
Interestingly, complex II (succinate dehydrogenase) is not increased, perhaps to further produce ATP 
through glutamate/malate-driven respiration via complex I, which is more efficient per molecule of 
glucose. Data are representative of n > 3. B) Oxygen consumption/ mitochondrial respiration rates (states 
III and IV) and RCR measured using polarographic oxygen electrode. State III respiration, in which ADP 
and substrate (for complex I, glutamate) are saturated, is indicative of maximal ETC respiration. The 
increased expression of OXPHOS proteins observed in DxR treated jurkats is accompanied by a 
commensurate increase in glutamate/malate-driven state III respiration. State IV respiration, or minimal 
respiratory capacity, is only marginally altered, suggesting very little proton leak or mitochondrial damage. 
Respiratory control ratio (RCR), a measure of ATP production efficiency via mitochondrial coupling, is 
increased with DxR treatment concentration in a dose dependent manner. Data represent the mean ± SD, n 





















Figure 4. A) Validation immunoblot of CRISPR MFN-2 knockout. Vector was shown to be effective in 
target gene knockout. Data is representative of n > 3. B) New acute median lethal dose established for 
MFN-2 KO jurkat t-cells. Compared to treated wildtype control (WT), MFN-2 KO cells demonstrate 
significantly lower LD50, decreasing from 0.81 M to 0.49 M, respectively. Data suggest that MFN-2 
mediated mitochondrial fusion contributes to jurkat t-cell insensitivity and subsequent survival. Data 













Doxorubicin (DxR) is a standard-of-care nonselective anthracycline molecule 
routinely used in the treatment of leukemia (21). In this study, we demonstrated that 
Jurkat leukemia cells, if they are to survive a DxR assault, must quickly change 
mitochondrial morphology, rates of oxidative phosphorylation, and respiratory capacity. 
Specifically, we show that mitochondrial fusion mediated by MFN-2 (but not MFN-1), as 
well as significant increases in expression for particular OXPHOS respiratory proteins 
and mitochondrial respiration rate, are required for Jurkat cell survival at median lethal 
DxR doses. Together these data suggest that mitochondrial dynamics, as well as their 
associated metabolic programs, play an important role in leukemia responses to DxR 
chemotherapy, and may also account for subsequent DxR chemoresistance and 
desensitization.  
As a DNA intercalator, DxR inhibits the action of topoisomerase II, generating 
DNA damage and thus preventing biosynthesis and additional cancer growth (22). 
Though effective in treating many cancers, its use is limited by several side effects, 
especially cardiomyopathy (23), which presents a need to maximize its efficacy by 
reducing its therapeutic dose concentration. At higher concentrations, previous works 
have linked DxR-induced mitochondrial dysfunction to cardiomyopathy development 
through decreased respiration of Jurkat cells at 5-10 M DxR (24). However, it has been 
estimated that typical plasma concentrations of DxR in patients is as low as 1-2 M (25), 
meaning a gap exists regarding mitochondrial action at smaller clinical concentrations.  
Mitochondria possess the capacity to fluctuate between structural morphologies 
based on cellular stresses, bioenergetic demand (26), and disease state. DRP-1 is 
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activated post-translationally by Cdk1/cyclin B-mediated phosphorylation of Serine-616 
(27), translocating to the mitochondrial outer membrane, homo-oligomerizing into a ring 
structure, and inducing morphological fission (28). This fission has been observed in 
several types of cancer (29,30,31), and studies have found DRP-1 expression to be 
correlated to mitotic cell cycle phases in which proliferation occurs (32). In our study, 
elevated levels of both total and phosphorylated DRP-1 in untreated Jurkats are consistent 
with this notion, as is the corresponding decreased expression of DRP-1 (Figure 2) and 
smaller proportion of G2/M phase cells (Figure 1) in the DxR treated groups. Conversely 
MFN-2, which induces outer mitochondrial membrane fusion, was observed to increase 
in treated cells, and while MFN-1 also increased, it was marginal in comparison (Figure 
2). Additionally, prohibitin protein 1 (PHB-1), which assembles at the mitochondria inner 
membrane to facilitate mitochondrial fusion and stabilize OXPHOS proteins (33), was 
found to increase with DxR treatment, particularly at 1 M (Figure 2). Together, these 
data suggest a role for mitochondrial dynamics in Jurkat responses to DxR, and in 
particular, implicate MFN-2 mediated fusion in insensitivity and survival.  
 Fused mitochondria are associated with oxidative phosphorylation-driven 
bioenergetics (34), and while healthy differentiated cells typically employ the OXPHOS 
metabolic program for energy, it is well known that cancer cells are aerobically 
glycolytic. Although less efficient at ATP generation per molecule of glucose, this 
transformation from oxidative metabolism to aerobic glycolysis, observed first by Otto 
Warburg, permits cancer cells to utilize several of the biosynthetic precursors required to 
support and sustain rapid proliferation (35). Our data corroborate this process, with a 
relatively small amount of OXPHOS respiratory chain proteins in the untreated group. 
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Interestingly, after all DxR treatments, expression of OXPHOS proteins, and especially 
Complex V, were dramatically increased, with complex II providing the lone exception 
(Figure 3A). The reasons for this preferential utilization of NADH and the proton pump 
  C  I  ,   ble explanation is that FADH2 electron 
transfer bypasses Complex I (36)     C  II,   
translocate protons and thus is a less efficient energy production method.  
We next assessed the relationship between increased OXPHOS respiratory protein 
expression and respiration rate (Figure 3B). In the presence of substrate (for Complex I-
driven respiration, glutamate/malate) and inorganic phosphate, mitochondria will 
consume oxygen. Upon adding exogenous ADP to the mitochondria in a reaction 
,    ,        
ADP into ATP. Assuming saturation of both substrate and ADP, mitochondrial 
respiration is limited only by the intrinsic activity of the respiratory chain itself, achieving 
maximal, or state III, respiration (37). When ADP levels are exhausted and the ATP:ADP 
ratio is very high, minimal respiratory capacity, or state IV respiration, can be measured; 
any oxygen consumption in this state corresponds exclusively to proton leak. Using a 
Clark-type polarographic oxygen electrode, we found that state III respiration was 
positively correlated to DxR concentration relative to control, corroborating the increased 
expression of respiratory complexes previously observed through immunoblot. Taken 
together, we observe a hastened respiratory rate facilitated by increased respiratory 
complex expression in response to DxR treatment, contrary to prior studies at higher DxR 
doses. Moreover, the increased RCR in treated cells indicates more efficient ATP 
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production and tighter mitochondrial coupling, suggesting that rather than damage 
mitochondria of surviving cells, DxR forces maximum efficiency.  
Finally, to determine the impact of observed MFN-2 mediated fusion in surviving 
cells, as well as the increase in OXPHOS, MFN-2 was knocked out using a CRISPR-
MFN2-KO vector, the action of which was validated by immunoblot (Figure 4A, B). A 
prior study found that while knockout or silencing of both MFN-1 and MFN-2 eliminates 
mitochondrial fusion, it results in defective cell growth and widespread heterogeneity of 
mitochondrial membrane potential; greater outcomes were achieved by knocking out only 
one (38). Having observed little MFN-1 modulation in response to DxR, MFN-2 was 
selected to inhibit mitochondrial fusion and OXPHOS, both of which have roles in 
chemo-resistant cancers (39, 40). Interestingly, when compared to treated wildtype, 
MFN-2 KO cells demonstrated significant drug sensitization to DxR (Figure 4B), with a 
reduced median lethal dose (0.81 M for treated wildtype, 0.49 M for treated KO). 
Our work here presents MFN-2 and mitochondrial fusion as targets for enhancing 
doxorubicin efficacy and increasing cell sensitivity to treatment, which with further 
research may provide opportunities to reduce adverse side effects and improve clinical 
outcomes. Moreover, our findings further implicate mitochondrial dynamics not only in 
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CHAPTER 4:  




 Idiosyncratic drug-induced liver injury (DILI) is a rare form of liver injury that 
occurs in patients taking therapeutic doses of drugs. While idiosyncratic hepatotoxic 
drugs are not structurally or chemically related, most drugs that cause DILI have been 
    rough inhibition of mitochondrial respiration, increased 
mitochondrial reactive oxygen species (ROS) generation, and other changes that disrupt 
mitochondrial homeostasis. In most cases, hepatocytes adapt to drug-induced 
mitochondrial stress by activating adaptation signaling pathways, including 
mitochondrial adaptive responses such as autophagy/mitophagy, mitochondrial 
remodeling, and alterations in mitochondrial fusion-fission. Due to these adaptations, 
drug intake alone is not sufficient to cause liver injury, with acetaminophen being the 
notable exception. Idiosyncratic DILI involves other extrinsic factors, including 
inflammation and the adaptive immune system. Inflammation may promote DILI because 
mitochondrial stress (i.e. increased mitochondrial ROS generation) induced by 
hepatotoxic drugs can inhibit adaptation/survival signaling pathways, such as NF- B, 
needed to withstand the cytotoxic effects of tumor necrosis factor-  ( NF)  
during inflammation. If mitochondrial and hepatocellular injury reach a critical threshold, 
death signaling pathways involving c-Jun N-terminal kinase (JNK) that target 
mitochondria are activated. JNK activation and translocation to mitochondria triggers the 
mitochondrial permeability transition (MPT) that results in hepatocyte death and liver 
injury. Mitochondria, therefore, play a critical role in all stages of DILI.  
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INTRODUCTION  
The liver is the major organ responsible for drug detoxification and consequently 
the major site of drug injury (1, 2). Drug-induced liver injury (DILI) is the leading cause 
of black box warnings, drug withdrawals, and clinical trial failures (1, 3, 4). DILI 
describes a condition where the medical intake of a drug(s) causes abnormal liver tests 
(i.e., increased serum ALT levels), which may lead to catastrophic consequences, 
including acute liver failure (5). While drugs that cause liver injury are not structurally or 
 ,          (6, 
7, 8). In most cases, mitochondrial stress caused by hepatotoxic drugs is not sufficient to 
cause liver injury. However, mitochondrial stress may alter signaling pathways including 
adaptation/survival pathways that sensitize hepatocytes to extrinsic factors, such as 
inflammation and the adaptive immune system, to trigger liver injury (8). This review 
will examine the critical role mitochondria play in mediating DILI.  
Overview of DILI  
 DILI is categorized into two broad categories: predictable and idiosyncratic. 
Acetaminophen (APAP) is one of the few marketed drugs that cause a predictable, dose-
dependent hepatotoxicity in animal models and in patients. APAP, due to unintentional or 
deliberate overdose, is the most common cause of drug-induced liver failure, accounting 
for ~46% of acute liver failure cases in the United States (9). Idiosyncratic DILI is the 
rare form of liver injury (1 in 1000 20,000) that occurs in patients taking therapeutic 
doses of drugs (1, 10). Idiosyncratic DILI is not strictly dose dependent, but a dose 
threshold generally exists, as a minimum dosage of drug (50 100 mg daily) is required 
for liver injury to occur. Idiosyncratic DILI is generally not observed in animal models, 
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as most drugs pass animal testing before being administered to patients. Idiosyncratic 
DILI is also generally not observed during clinical trials due to insufficient population 
sizes (~low thousands) (7, 10). Consequently, only when a drug becomes consumed by a 
large number of patients does idiosyncratic DILI become unequivocally recognized. 
Idiosyncratic DILI accounts for ~13% of acute liver failure cases in the United States.  
The underlying mechanisms of why a small subpopulation of patients develops 
liver injury with therapeutic drug doses, while the majority of patients do not, are 
complex. Idiosyncratic DILI results from the convergence of multiple risk factors, such 
as genetics, age, gender, diet, and infections (5, 11). Recent genome-wide association 
studies (GWAS) have shown that patients with certain human leukocyte antigen (HLA; 
the human equivalent of MHC) haplotypes are susceptible to idiosyncratic DILI caused 
by a number of drugs, including lumiracoxib, lapatinib, ticlopidine, amoxicillin-
clavulanate, flucloxacillin, and ximelagatran (12, 13, 14, 15, 16, 17, 18). For example, the 
HLA-D B1*1501       -clavulanate-
induced DILI, while HLA-DRB1*5701 increases the risk for flucloxacillin-induced DILI. 
The strong relationship between hepatotoxic drugs and HLA polymorphisms suggests 
that the adaptive immune system plays an important role in a large number of 
idiosyncratic DILI cases (8). A recent study has shown that abacavir, which causes 
hypersensitive reactions, binds within the F pocket of the peptide-binding groove of the 
HLA receptor (HLA-B*57:01 haplotype) (19). Thus, patients with the HLA-B*57:01 
haplotype have a greater potential for auto-immune reactions because the drug is 
presented on the HLA receptor to T-cells (20). Although patients with certain HLA 
haplotypes have increased risk for DILI, overall rates remain low for most drugs (21). 
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Other extrinsic factors (infections, inflammation, diet) also play important roles in the 
development of idiosyncratic DILI (5, 7).  
 
Drugs that Cause DILI Stress Mitochondria  
Mitochondria  as major generators of ATP, key regulators of apoptosis, and 
major sources of reactive oxygen species (ROS)  play a central role in hepatocyte 
survival (8; 22). Stress or injury to mitochondria has profound effects on ATP and ROS 
levels and can trigger the release of pro-death proteins such as cytochrome c (4). 
Mitochondria play a critical role in DILI during all stages of the pathology: (1) inhibition 
of mitochondrial function by drugs or reactive metabolites that can initiate DILI, (2) 
adaptation pathways involving mitochondria that help most patients tolerate drugs, and 
(3) activation of death signaling pathways involving c-Jun N-terminal kinase (JNK) that 
targets mitochondria to cause hepatocyte death and  liver injury. Most drugs that cause 
DILI, predictable or idiosyncratic, have been shown to stress or injure mitochondria by 
disrupting mitochondrial function (6, 8, 23).  
Hepatotoxic drugs, or drug metabolites formed from metabolism by cytochrome 
P450 (CYP450), have been shown to inhibit mitochondrial respiration, disrupt beta-
oxidation, deplete 110 mitochondrial glutathione (GSH), increase mitochondrial ROS 
generation, and cause other mitochondrial disruptions that stress or injure mitochondria 
(8). However, in most cases, mitochondrial stress induced by a drug is not sufficient to 
cause hepatotoxicity, and the majority of patients taking drugs do not develop liver 
injury. Most patients taking idiosyncratic        
liver injury by upregulating adaptation signaling pathways, many involving 
mitochondria. Mitochondrial adaptation pathways include autophagy/mitophagy, 
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mitochondrial remodeling, and mitochondrial fusion-fission (Figure 1). A small fraction 
  ( )              
adapt because of inflammation and other extrinsic factors. When mitochondrial and 
hepatocellular injury reaches a critical threshold, death signaling pathways involving 
JNK become activated and target mitochondria (8, 24). The binding of activated JNK 
(phosphorylated JNK) to mitochondria triggers the mitochondrial permeability transition 
(MPT), which causes mitochondrial swelling and release of cytochrome c that results in 
hepatocyte death and liver injury (8).  
DILI has been difficult to study due to the rarity of the disease in patients and lack 
of animal models (1, 24). Because APAP is one of the few marketed drugs that cause a 
predictable, dose-dependent hepatotoxicity, most of our mechanistic knowledge on the 
role of mitochondria in DILI has come from work with APAP in cultured hepatocytes 
and in animals (1). While APAP treatment causes very predictable liver injury, insights 
regarding idiosyncratic DILI have been obtained using APAP in animal models, since its 
hepatotoxicity is similarly affected by age, sex, diet, inflammation caused by bacteria and 
viruses, and genetic factors (7; 25). Because the APAP animal model has revealed a great 
deal of information regarding the role of mitochondria in drug-induced hepatotoxicity, we 









Figure 1 Critical role of mitochondria in DILI. Hepatotoxic drugs or drug metabolites formed from 
metabolism by cytochrome P450 (CYP450) have been shown to inhibit mitochondrial respiration, disrupt 
beta-oxidation, increase mitochondrial ROS generation, and cause other types of mitochondrial disruptions 
that stress or injure mitochondria. In most cases, mitochondrial stress induced by a drug is not sufficient to 
cause hepatotoxicity, because adaptation pathways including autophagy/mitophagy, mitochondrial 
remodeling, and mitochondrial fusion-fission become activated. Mitochondrial fusion-fission could also 
potentially play a deleterious role by initiating mitochondrial fragmentation that promotes hepatocyte death. 
A small number of patients may progress to severe liver injury due to failure to adapt resulting from 
inflammation and other extrinsic factors. When mitochondrial and hepatocellular injury reaches a critical 
threshold, death signaling path- ways involving JNK that target mitochondria become activated. Activated 
JNK binds to Sab on the outer mitochondrial membrane to trigger the mitochondrial permeability transition 
(MPT), which causes mitochondrial swelling, and release of cytochrome c that results in hepatocyte death 








CENTRAL ROLE OF MITOCHONDRIA IN APAP-INDUCED LIVER INJURY  
Mitochondrial injury plays an essential role in APAP-induced liver injury. It has 
been demonstrated that serum levels of mitochondrial biomarkers (mtDNA, glutamate 
dehydrogenase) are predictive of patients surviving APAP-induced acute liver failure 
(26). Patients with greater mitochondrial injury that causes the release of mitochondrial 
constituents into the plasma are much more likely to suffer acute liver failure. 
Consequently, there has been increased research exploring mitochondria-targeted 
therapies, such as mitochondria-targeted antioxidants (Mito-TEMPO), and electron 
transport mediators, such as methylene blue, to protect against APAP-induced liver injury 
in animal models (27; 28).  
Inhibition of Mitochondrial Bioenergetics by APAP  
APAP hepatotoxicity can be directly attributed to the formation of N-acetyl-p- 
benzo-quinoneimine (NAPQI), a reactive metabolite generated during the metabolism of 
APAP by CYP450, primarily by the CYP2EI isoform (29; 30). NAPQI is a highly 
reactive metabolite that forms covalent bonds with protein thiols and nonprotein thiols 
including glutathione (GSH), the major antioxidant in cells. At hepatotoxic doses of 
APAP, NAPQI causes severe depletion of GSH in the cytoplasm and mitochondria, 
which contain separate GSH pools (2; 31). APAP treatment has also been shown to 
decrease levels of glutamate cysteine ligase (GCL), the rate-limiting enzyme in GSH 
synthesis, further depleting GSH in the liver (32). The depletion of mitochondrial GSH is 
considered the critical event in APAP hepatotoxicity, as it results in the partial inhibition 
of mitochondrial respiration and enhanced mitochondrial ROS generation  important in 
activating JNK death signaling. NAPQI may directly bind thiols in the respiratory 
 128 
complexes to inhibit mitochondrial respiration (33), with complex II being particularly 
sensitive to NAPQI inhibition (27).  
APAP treatment enhances mitochondrial ROS generation by (1) reducing the 
efficacy of GSH peroxidase, which utilizes GSH to detoxify H2O2, and (2) by inhibiting 
mitochondrial respiratory complexes, which generally enhance superoxide generation 
(24; 34, 35). There is a critical threshold for mitochondrial GSH depletion that 
determines whether liver injury occurs. If the threshold is reached (>90%), extensive 
NAPQI inhibition of mitochondrial proteins and/or enhanced mitochondrial H2O2 
production will activate the JNK death signaling cascade that causes severe liver injury 
(8). When the GSH threshold is not reached, adaptation pathways involving nuclear 
factor (erythroid-derived 2)-like-2 (Nrf-2) help mitochondrial and liver GSH levels 
recover, resulting in little liver injury (36). Low non-hepatotoxic doses of APAP have 
been shown to cause reversible mitochondrial depolarization in the liver, without 
hepatocyte necrosis or ALT release (37).  
 
Adaptation of Mitochondria to Promote Survival in Response to APAP  
Adaptive mechanisms in the liver, including mitochondrial adaptation, may be 
crucial in patients consuming even therapeutic doses of APAP (4 grams daily). One study 
reported that the majority of patients (up to 81%) receiving therapeutic doses of APAP 
initially develop elevated plasma ALT levels (38). However, adaptation mechanisms 
appear to protect the majority of patients from APAP, and in most cases continuous 
APAP intake does not result in liver injury. Mitochondrial adaptation mechanisms 
including enhancement of mitochondrial GSH levels, autophagy/mitophagy, 
mitochondria remodeling, and alteration of mitochondrial fusion-fission have been 
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characterized in various liver pathologies. Next, the importance of mitochondrial 
adaptation mechanisms that may be important in protecting against APAP hepatotoxicity 
will be examined.  
Enhancement of Mitochondrial GSH Levels  
Mitochondria lack enzymes necessary for GSH synthesis, and consequently GSH 
must be transported into the mitochondrial matrix (31). Interestingly, once GSH is 
oxidized to GSSG, it appears to become trapped inside the mitochondrial matrix: GSSG 
transporters have not been observed in mitochondria (39; 40). We have demonstrated that 
feeding respiratory substrates (i.e., glutamate/malate, succinate, etc.) into the electron 
transport chain generate NADPH, which is essential in maintaining GSH and protein 
thiols in their reduced forms, as well as reversing post-translational modifications such as 
S-glutathionylation and S-nitrosylation (40; 41). During times of oxidative stress, 
respiratory substrates are critical in keeping the mitochondrial redox environment 
reduced and fully functional (40).  
The transcription factor Nrf-2 plays a central role in adaptation to APAP in the 
liver by replenishing cytoplasmic and mitochondrial GSH levels (36). Nrf-2 is usually 
bound in the cytoplasm to Kelch-like ECH-associated protein 1 (Keap1), a redox-
sensitive anchoring protein. Also attached to Keap1 is a cullin-dependent E3 ubiquitin 
ligase complex (Cu3) that facilitates the ubiquitination of Nrf-2. Keap1 binds newly 
synthesized Nrf-2, which results in Cu3-dependent ubiquitination and proteasomal 
degradation (36; 42). Consequently, Nrf-2 has an extremely short half-life (10 30 min). 
The binding of critical thiols in Keap1 (~25 cysteine residues) by NAPQI and other 
electrophiles causes a conformational change that prevents Nrf-2 ubiquitination and 
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degradation (8). Therefore, the NAPQI-induced conformational change of Nrf-2 keeps 
Keap1 occupied without being degraded, allowing newly synthesized Nrf-2 to translocate 
to the nucleus and bind to the antioxidant response element (ARE), a DNA sequence in 
the promoter of antioxidant enzymes such as GCL (36; 42). Nrf-2 upregulation of GCL is 
essential in replenishing mitochondrial and cytoplasmic GSH following even therapeutic 
doses of APAP. Even low, nontoxic doses of APAP have been shown to activate Nrf-2 
and increase GSH synthesis in the liver of mice (43).  
 
Autophagy/Mitophagy  
Autophagy is a lysosome-mediated process where intracellular proteins and 
organelles, including mitochondria, are degraded and recycled (44). Mitophagy is a 
selective form of autophagy, where damaged mitochondria are removed and degraded by 
lysosomes (45). Both autophagy and mitophagy are enhanced by various stresses, 
including starvation. Since APAP treatment is known to cause mitochondrial dysfunction, 
it is not surprising that both autophagy and mitophagy occur following hepatotoxic doses 
of APAP. Activation of autophagy and mitophagy is believed to be protective, as 
damaged mitochondria are removed, especially those with enhanced ROS generation 
(46). Pharmacological inhibition of autophagy aggravates APAP-induced liver injury 
(47), while enhancement of autophagy using rapamycin protects against APAP-induced 
liver injury in mice. AMP-activated protein kinase (AMPK), which is regulated by 
protein kinase C (PKC) (48), is believed to promote autophagy in the liver and help 
protect against APAP (48). Mitophagy has not been extensively characterized during 
APAP hepatotoxicity but is believed to be mediated by Parkin in the liver (49).  
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Mitochondria Remodeling  
The mitochondrial respiratory chain can undergo remodeling and biogenesis 
to increase respiratory capacity in response to injury (8; 50). We observed that chronic 
alcohol feeding in mice and rats caused various types of mitochondrial remodeling, 
including alterations in respiratory complex proteins, increased mitochondrial NADH-
NADPH levels, and increased mitochondrial respiration as adaptations to alcohol (51, 
52). Mitochondrial remodeling is likely mediated by proliferator-activated receptor 
gamma coactivator-1  (PGC-1 ), a coactivator and master regulator of mitochondria (50; 
51). Mitochondrial injury in the liver caused by the hepatotoxin CCl4, which induces 
extensive lipid peroxidation, has similarly been shown to increase mitochondrial 
respiration and levels of respiratory complexes in the liver (53; 54). Thus, APAP 
treatment, which injures mitochondria and enhances mitochondrial degradation by 
autophagy and mitophagy, is likely to activate PGC-1  and other mitochondrial 
biogenesis pathways to promote mitochondrial remodeling and biogenesis. However, to 
our knowledge a detailed study examining mitochondrial remodeling and biogenesis 
following APAP treatment has not been performed in the liver, and further studies are 
needed.  
ALTERATION OF MITOCHONDRIAL FUSION-FISSION 
Mitochondria constantly undergo fusion-fission in order to exchange 
mitochondrial constituents including mtDNA, respiratory complexes, mitochondria 
proteins, and GSH (55; 56). Mitochondrial fusion and fission are primarily controlled by 
four highly conserved GTPases: mitofusins (Mfn1, Mfn2) in mitochondrial outer 
membranes promote fusion; optic atrophy (Opa1) in the inner membranes promotes 
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fusion; and dynamin-related protein 1 (Drp1) from the cytoplasm translocates to 
mitochondria to initiate fission (55; 57). Stress can alter mitochondrial fusion-fission 
rates and mitochondrial morphology, which can promote cell death or cell survival 
depending on the circumstances. Mitochondrial fission mediated by Drp1 can promote 
mitochondrial fragmentation and cell death (55; 58). Conversely, alterations in 
mitochondrial fusion-fission can promote cell survival, in cases such as starvation, where 
mitochondrial fission decreases to produce elongated mitochondria with greater cristae 
surface areas that increase respiration and ATP production (59).  
APAP hepatotoxicity is associated with dramatic morphological alterations in 
mitochondria, including both fragmentation and elongation (60), as well as formation of 
spheroid-shaped mitochondria (61; 62). The implications of these mitochondrial 
morphological changes caused by hepatotoxic doses of APAP remain uncertain. It has 
been suggested that spheroid-shaped mitochondria formation mediated by Mfn1or Mfn2 
may be a protective mechanism of inactivating damaged mitochondria (49), but further 
research is needed. ROS appear to be important in triggering mitochondrial 
morphological changes and spheroid-shaped mitochondria formation in hepatocytes (61). 
Drp1 has been observed to translocate to mitochondria very early during APAP 
hepatotoxicity (63), which may help explain some observations of fragmented 
mitochondria during APAP hepatotoxicity. However, the importance of this Drp1 
translocation to mitochondria during APAP hepatotoxicity requires further examination. 
Overall, mitochondrial morphological changes are very prominent during APAP-induced 
liver injury, but whether these changes play an adaptive, detrimental, or inconsequential 
role in hepatotoxicity needs further exploration.  
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DEATH SIGNALING PATHWAYS TARGETING MITOCHONDRIA  
 
 JNK Activation and Translocation to Mitochondria  
Despite adaptive mechanisms, if mitochondrial GSH depletion reaches a critical 
threshold, the death signaling pathway involving JNK becomes activated 
(phosphorylation). Activated JNK targets mitochondria and plays a critical role in 
promoting mitochondrial dysfunction and liver injury during APAP hepatotoxicity. JNK 
inhibition or silencing protects against APAP-induced liver injury, despite excessive 
mitochondrial GSH depletion and covalent binding in the liver (24). JNK plays an 
important role in stress response; however, when JNK activation is sustained, it promotes 
mitochondrial dysfunction and cell death (7, 64). Increased mitochondrial ROS 
generation mediated by NAPQI is believed to activate JNK during APAP-induced liver 
injury through a complex feed-forward mechanism. The maximal activation of JNK 
appears to involve a number of upstream kinases, including PKC- , receptor-interacting 
serine/threonine-protein kinase 1 (RIP1), glycogen synthase kinase-3  (GSK-3 ), mixed-
lineage kinase-3 (MLK3), and apoptosis signal-regulating kinase 1 (ASK1)  (31; 48; 63; 
65;  66). Silencing any one of these kinases in mice inhibits JNK activation and 
translocation to mitochondria to protect against APAP hepatotoxicity. Activated JNK 
translocates to mitochondria and binds SH3 homology associated BTK-binding protein 
(Sab or SH3BP5), a scaffold protein on the outer membrane of mitochondria that contains 
a kinase interaction motif (67; 68). The binding of JNK to Sab further impairs 
mitochondrial respiration and enhances mitochondrial ROS generation by activating a 
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signaling cascade involving mitochondrial protein tyrosine phosphatase, nonreceptor type 
6 (SHP1), and mitochondrial Src (69). 
Once critical levels of JNK translocate to mitochondria, the mitochondrial 
permeability transition (MPT) is triggered, causing mitochondrial swelling and release of 
cytochrome c that results in hepatocyte death and liver injury. The exact mechanism of 
how JNK triggers MPT remains to be fully characterized. APAP hepatotoxicity is an 
active process, since JNK signaling pathways must be activated for liver injury to occur. 
This is somewhat surprising, as APAP-induced liver injury occurs primarily through 
necrosis rather than apoptosis (24; 70). Clinical studies have shown that circulating levels 
of full length K18 (Fl-K18), a marker of necrosis, were much higher (85%) than the 
cleaved K18 fragment (cK18), a marker of apoptosis (15%), in patients suffering from 
APAP hepatotoxicity (71). These findings correspond with animal studies that have 
demonstrated that APAP hepatotoxicity occurs primarily through hepatocyte necrosis. 
The fact that JNK actively mediates hepatocyte death challenges the traditional view that 
APAP hepatotoxicity is a passive process due to overwhelming hepatocellular injury 
caused by NAPQI (7; 8). APAP hepatotoxicity can therefore be viewed as a type of 
  (8; 72).  
 
Mitochondrial Targeting by Other Kinases  
JNK is not the only kinase that has been shown to translocate to mitochondria 
during APAP-induced liver injury. PKC- , GSK-3 , and RIP1 have all been shown to 
translocate to liver mitochondria following hepatotoxic doses of APAP. However, it has 
been difficult to decipher whether the translocation of these kinases contributes to 
mitochondrial dysfunction during APAP hepatotoxicity, since silencing these kinases 
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inhibits JNK activation and translocation to mitochondria. For example, PKC-  
translocates to mitochondria and phosphorylates mitochondrial proteins. However, 
silencing PKC-  inhibits JNK activation and translocation during APAP hepatotoxicity, 
suggesting that PKC-  is important in activating JNK. In other injury models, PKC-  
translocation to mitochondria appears to play a protective role in cardiac ischemic injury 
by phosphorylating mitochondrial proteins such as pyruvate dehydrogenase, while PKC-
, which inhibits pyruvate dehydrogenase, appears to promote cardiac ischemic injury 
(73; 74; 75; 76). Similarly, GSK-3  translocation to mitochondria is believed to be 
important in mediating ischemia-reperfusion injury in the heart by promoting MPT (77; 
78; 79). Therefore, the translocation of other kinases  such as PKC- , GSK-3 , and 
RIP1  to mitochondria following APAP treatment may play a role in APAP 
hepatotoxicity, but further studies are needed to delineate their effects from JNK (31).  
Mitochondrial Regulation by Bcl-2 Family Members  
Mitochondria are the organelles where members of the B-cell lymphoma-2 (Bcl-
2) family exert their apoptotic or anti-apoptotic effects. Bax, a proapoptotic member of 
the Bcl-2 family, has been shown to translocate to liver mitochondria during APAP 
hepatotoxicity, possibly through a JNK-dependent pathway (24). However, Bax knockout 
mice exhibit the same level of liver injury as control mice following APAP treatment, 
suggesting that Bax is not essential for mitochondrial dysfunction and hepatocyte death 
(80). JNK translocation to mitochondria has been suggested to phosphorylate and 
inactivate Bcl-2 and Bcl-xl, two anti-apoptotic proteins on the outer membrane of 
mitochondria (24; 81).  
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Induced myeloid leukemia cell differentiation protein (Mcl-1), an anti-apoptotic 
Bcl-2 family member, is also degraded in the liver during APAP hepatotoxicity (31). 
Silencing Mcl-1 in the liver causes spontaneous apoptosis in hepatocytes (82), suggesting 
that the loss or inactivation of anti-apoptotic Bcl-2 family members from mitochondria 
may contribute to hepatocyte death following APAP treatment. Taken together, many 
proteins (kinases, Bcl-2 family members) translocate to mitochondria, while anti-
apoptotic Bcl-2 members become inactivated in mitochondria. All of these events may be 
contributing to mitochondrial dysfunction during APAP hepatotoxicity, but currently 
only JNK translocation to mitochondria has been shown to be critical in causing 
mitochondrial dysfunction essential for liver injury.  
 
ROLE OF MITOCHONDRIA IN IDIOSYNCRATIC DILI   
Idiosyncratic DILI likely involves mitochondrial stress, mitochondrial 
adaptations, and death signaling pathways targeting mitochondria as observed with 
APAP (Figure 1). While APAP is unique in that its toxicity is dependent on severe GSH 
depletion, many other features of APAP hepatotoxicity are likely to occur during liver 
injury caused by other hepatotoxic drugs (8). Thus, hepatotoxic drugs may have many 
general shared characteristics, as well as some unique drug-specific features (i.e., 
metabolism, reactive metabolites, etc.). Since idiosyncratic DILI is rare and lacks good 
animal models, our overall knowledge is limited and more open to speculation.  
Inhibition of Mitochondrial Homeostasis by Idiosyncratic Hepatotoxins  
  Most drugs that cause idiosyncratic DILI have been shown to stress or injure 
mitochondria. Reactive metabolites formed during drug metabolism, rather than the drug 
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itself, may often be disruptive to mitochondria in hepatocytes (1; 10). Many reactive 
metabolites can also directly cause oxidative stress. For example, troglitazone forms a 
reactive metabolite that forms adducts with molecules like GSH (83). Table 8.1 shows 
idiosyncratic hepatotoxic drugs that disrupt mitochondrial function in hepatocytes or 
isolated mitochondria. A wide range of mitochondrial functions including mitochondrial 
electron transport, beta-oxidation, and protein synthesis can be inhibited by hepatotoxic 
drugs. The majority of drugs listed in Table 8.1 do not cause liver injury (i.e., increased 
ALT, histology) when given to healthy animals, though mitochondrial stress can 
sometimes be observed in the liver. For example, chronic treatment of nimesulide to mice 
increased cytochrome c release from mitochondria in the liver, but ALT levels and 
histology remained similar to control (84).  
In most cases, mitochondrial inhibition by idiosyncratic hepatotoxic drugs listed 
in Table 8.1 is only observed in cultured hepatocytes or with isolated liver mitochondria. 
Antimicrobials cause ~46% of idiosyncratic DILI cases, possibly because mitochondria 
are of bacterial ancestry and still share many genetic and structural similarities with 
bacteria. A limited amount of human data suggests that mitochondrial abnormalities 
occur in the liver during idiosyncratic DILI. Tolcapone-induced DILI has been observed 
to be associated with mitochondrial swelling in the livers of patients (87). Electron 
microscopy studies have similarly demonstrated that aspirin-     
linked with abnormal mitochondria in the liver (85; 86). Large screening studies have 
also confirmed that inhibition of mitochondrial homeostasis occurs for the majority of 
idiosyncratic hepatotoxic drugs.  
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Screening for drugs (300 tested) that cause oxidative stress and disrupt 
mitochondrial homeostasis (ROS, mitochondrial membrane potential, etc.) in human 
hepatocytes revealed that 50 60% of idiosyncratic hepatotoxic drugs caused 
mitochondrial perturbations, whereas non-hepatotoxic drugs were shown not to affect 
mitochondria (0 5%) (88). Similarly, screenings utilizing isolated mouse liver 
mitochondria showed that most drugs that cause idiosyncratic DILI disrupt mitochondrial 
function (i.e., membrane potential, respiration, cytochrome c release, etc.; 89% positive 
predictive value) (89). Thus, these types of mitochondrial screening studies, in 
    ( , , .)   
identify idiosyncratic hepatotoxins during drug development (90; 15).  
If a majority of hepatotoxic drugs disrupt mitochondrial homeostasis, the question 
remains why liver injury only occurs in a small number of patients, while the majority 
remains unaffected. It is clear that mitochondrial stress alone is not enough to cause liver 
injury in most cases, and other factors contribute to DILI. The mechanism of 
idiosyncratic DILI is multifactorial (genetics, age, gender, diet, infections), and it is 
possible that the same drug could cause DILI through different mechanisms in different 
patients. Genetic alterations that predispose patients to oxidative stress appear to cause 
liver injury in a number of idiosyncratic hepatotoxins. Mice that are heterozygous for 
Mn-superoxide dismutase (SOD 2+/- mice) represent an animal model with greater 
mitochondrial oxidative stress, due to reduced levels of mitochondrial SOD responsible 
for clearing superoxide in the matrix. Two idiosyncratic hepatotoxic drugs (troglitazone, 
flutamide) were shown to cause liver injury in SOD 2+/- mice but not in wild-type mice 
(91; 92). It must be noted that troglitazone-induced liver injury is somewhat controversial 
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in this model (93). Patients with mutations in Mn-SOD, or mutations in GSH peroxidase 
(GPX1) responsible for detoxification of H2O2, are at greater risk for developing 
cholestatic DILI (94). Similarly, patients, pre dominantly women, with mutations in 
glutathione S-transferase (GST) have an increased risk for developing idiosyncratic DILI 
regardless of the type of drug involved (94). Genetic alterations represent only one 
contributing factor to idiosyncratic DILI, and the failure of adaptation pathways due to 
extrinsic factors, such as infections, may also be important.  
 
 Mitochondrial Adaptation During Idiosyncratic DILI  
Clinical studies suggest that the liver readily adapts to chronic drug intake. 
Idiosyncratic hepatotoxic drugs often cause higher rates of mild, asymptomatic, and 
transient elevated serum ALT levels that disappear with continuous drug treatment (21; 
95). Drug screening studies in primary hepatocytes have shown that idiosyncratic 
toxicants (troglitazone, trovafloxacin) alter gene expression patterns much more than 
their non-hepatotoxic counterparts, possibly due to the mitochondrial stress induced by 
hepatotoxic drugs (96; 97). Many of these signaling changes in hepatocytes likely involve 
similar adaptation mechanisms previously characterized for APAP. Unfortunately, very 
little information regarding mitochondrial adaptation is available for most drugs that 
cause DILI due to the lack of reliable animal models. There is some evidence that many 
hepatotoxic drugs cause changes in mitochondrial morphology. 
 In primary hepatocytes, chloramphenicol treatment induces the formation of 
large mitochondria (mega-mitochondria) associated with lower respiration (98). Mega-
mitochondria with enhanced H2O2 generation were observed with troglitazone treatment, 
but not with its non-hepatotoxic counterparts (pioglitazone, ciglitazone) (99). Finally, 
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trovafloxacin treatment has been shown to downregulate many mitochondrial genes, 
including Mfn1, suggesting that mitochondrial morphological changes occur in 
hepatocytes (100). Given that many drugs that cause DILI inhibit mitochondrial 
respiration and/or induce oxidative stress  both of which are known to trigger 
mitochondrial morphological changes  these observations of mitochondrial 
morphological alterations are not surprising. Whether these mitochondrial morphological 
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Failure of Adaptation Signaling Pathways Due to Drug Intake  
Inflammation caused by bacteria or viruses is a clinically important risk factor for 
the development of idiosyncratic DILI (5; 101). Some idiosyncratic hepatotoxic drugs 
may promote liver injury by inhibiting signaling pathways involved in adaptation to 
inflammation, particularly cytokines such as tumor necrosis factor-  (TNF) released 
during inflammation (102). TNF binding to TNF receptors in hepatocytes simultaneously 
activates a cell death signaling pathway and a survival/adaptation pathway. The death 
signaling pathway involves JNK activation and translocation to mitochondria that 
perpetuate a self-amplifying loop, similar to that observed during APAP hepatotoxicity 
(102). TNF is not normally toxic to hepatocytes because TNF also activates 
survival/adaptation pathways involving NF- B, which transcribes genes (GAPDD45b, 
XIAP, A20) and antioxidant proteins (Mn-SOD, ferritin) responsible for turning off JNK 
and promoting cell survival (102; 103; 104). Consequently, NF- B activation allows 
hepatocytes to adapt to TNF released during inflammation, and JNK activation is 
transient. However, oxidative stress and/or inhibition of mitochondrial respiration 
associated with many idiosyncratic hepatotoxins has been shown to inhibit NF- B 
activation and sensitize hepatocytes to TNF-induced apoptosis (105; 106; 107; 108). 
Thus, it is not surprising that APAP and the idiosyncratic toxicant chlorpromazine have 
been shown to sensitize cultured hepatocytes to TNF- induced apoptosis (109).  
The failure of hepatocytes to adapt to TNF has also been observed in vivo. 
Idiosyncratic hepatotoxic drugs (chlorpromazine, trovafloxacin, ranitidine) that do not 
normally cause liver injury in rats will induce liver injury when co-treated with a 
sublethal dose of lipopolysaccharide (LPS), which activates the innate immune system 
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and promotes TNF secretion (110; 111; 112). The sensitizing effects of LPS to 
idiosyncratic hepatotoxic drugs were shown to be mediated by TNF released by the 
innate immune system (100). Therefore, drugs that induce mitochondrial stress and/or 
enhanced ROS generation are likely blocking adaptation signaling pathways (NF- B) 
and/or helping to sustain JNK activation to sensitize hepatocytes to TNF-induced 
apoptosis in vivo (8). With atorvastatin, a statin associated with idiosyncratic liver injury, 
the opposite phenomenon is observed: inflammation inhibits drug-induced adaptation 
pathways (113). In ApoE-/- mice, atorvastatin treatment was shown to induce Nrf-2 
translocation to the nucleus and upregulate antioxidant enzymes (catalase, SOD). 
Inflammation induced by casein injection was observed to inhibit Nrf-2 activation 
induced by atorvastatin, leading to liver injury including hepatic steatosis and fibrosis. 
Given that both hepatotoxic drugs and inflammation are associated with oxidative stress 
that can inhibit adaptation signaling pathways (Nrf-2, NF- B) and sustain JNK 
activation, it is easy to see how these two factors may work synergistically to promote 
liver injury. Surprisingly, the therapeutic potential of antioxidants to protect against 
idiosyncratic DILI has not been extensively explored, especially since vitamin E has been 
shown to protect against nonalcoholic steatosis (NASH) in patients (114). The increased 
risk of DILI that occurs with certain HLA haplotypes suggests that the adaptive immune 
system is important in mediating DILI caused by some drugs. Certain haplotypes of 
HLA, which bind drugs or reactive metabolites, may promote the adaptive immune 
system to attack the liver (10). These drug-induced autoimmune reactions may increase 
during inflammation, when the immune system is at a heightened state. Drug-induced 
mitochondrial dysfunction may also be sensitizing hepatocytes to components of the 
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adaptive immune system, such as cytotoxic T-cells (8). It is also possible that 
idiosyncratic hepatotoxic drugs may inhibit adaptation to TNF and other cytotoxic agents 
(i.e., FasL, perforin, granulysin, granzyme) released by the adaptive immune system. 
Clearly the role the immune system plays in idiosyncratic DILI merits further 
investigation.  
 
Mitochondria Targeting by Death Signaling Pathways During Idiosyncratic DILI  
 Idiosyncratic DILI caused by drug intake and extrinsic factor(s) is likely to 
involve death signaling pathways, such as JNK, once substantial mitochondrial and 
hepatocyte injury occurs. JNK is a strong candidate to mediate DILI caused by a wide 
range of drugs since it plays a central role in many liver pathologies. JNK plays a critical 
role in hepatocellular injury caused by bile acids, fatty acids, ER stress, TRAIL-Fas, 
ischemia/reperfusion, and TNF-induced liver injury in vivo (Con A plus D-
galactosamine, LPS plus D-galactosamine, and TNF plus D-galactosamine) (64; 115; 
116; 117, 68). At sufficient levels, JNK translocation to mitochondria will induce either 
MPT or mitochondrial outer membrane permeabilization (MOMP) to trigger hepatocyte 
death. Along with JNK, Bcl-2 family members including Bax and Bcl-xl are likely to 
determine if MPT or MOMP occurs. While we hypothesize that JNK plays a central role 
in mediating idiosyncratic DILI caused by many drugs, further studies are needed.  
CONCLUSION 
DILI appears to involve mitochondria during all stages of the disease (88; 89). 
Although idiosyncratic hepatotoxic drugs are not structurally or chemically related, most 
   DILI  . I   ,     
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drug-induced mitochondrial stress by activating adaptive signaling pathways, including 
mitochondrial adaptation responses such as autophagy/mitophagy, mitochondrial 
remodeling, and alterations in mitochondrial fusion-fission. While mitochondrial stress, 
such as increased mitochondrial ROS generation, may not be sufficient to trigger 
hepatocyte death, it may inhibit adaptation/survival signaling pathways (NF- B, Nrf-2) 
needed to survive extrinsic factors such as inflammation. After a critical threshold of 
mitochondrial and hepatocellular injury occurs, JNK is activated and targets 
mitochondria to induce MPT or MOMP, leading to cell death. Thus, mitochondria are the 
central points where oxidative injury, pro-death proteins, and adaptation pathways 
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DOXORUBICIN-INDUCED MITOCHONDRIAL REMODELING AND T-CELL 







The following chapter is the manuscript of American Cancer Society grant proposal 
to which I made significant contributions. The grant synthesizes doxorubicin-induced 
mitochondrial fusion data from Chapter 3 with our preliminary study data pertaining to 
naïve T cell differentiation into Th17 subsets. Specifically, the novelty of this grant is 
founded on assimilating the phenomena of mitochondrial remodeling observed in Chapter 
3 into emerging immunometabolism research of mitochondrial dynamics in T cell 





A. SPECIFIC AIMS 
 
1.) Demonstrate changes in mitochondrial morphology and metabolic reprograming in 
surviving doxorubicin (DxR)-applied cancer cells by identifying expression changes 
in the protein mediators employed for that survival. The goal of this specific aim is 
to identify mitochondrial morphology proteins utilized by leukemias/mature 
cancerous t-cells to survive small-molecule chemotherapy assaults (DxR), as well as 
provide protein targets that allow for increased sensitivity to chemo-toxins. 
Specifically, the GTPases Dynamin-1-like protein/DRP-1 (responsible for 
mitochondrial fission) and mitofusin-2/MFN-2 will be assessed for modulation. 
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Cancer cells- including Jurkats- employ aerobic glycolysis (a metabolic scheme 
accompanied by fissed mitochondria) in favor of oxidative phosphorylation (fused 
mitochondria), so respiratory chain complexes I-V will also be examined for changes 
to assess glycolytic/OXPHOS reprogramming.  
2.) Determine the role of protein mediators of mitochondrial morphology and metabolic 
reprogramming in chemotherapy survival and sensitivity via modulation of 
expression of those proteins. Specific Aim 1 seeks to elucidate protein targets 
involved in cancer t-cell survival. In this specific aim, the effect of mitochondrial 
morphology protein mediators DRP-1, MFN-1, and MFN-2 will be determined 
through their modulation via CRISPR KO technology. Once identified, this Aim will 
uncover specific mitochondrial morphology mediator actions essential for increased 
survivability, both from upstream and downstream signaling. The identification of 
these proteins is critical in developing pre-treatments, other knockouts, and inhibitors 
to increase DxR sensitivity. Upstream therapeutic targets will focus on mitochondrial 
morphology and metabolic reprograming, while downstream therapeutic targets will 
concentrate on cell reversal of DxR-induced apoptosis. In particular, we suspect that 
through deletion of MFN-2, cancer cells unable to fuse mitochondria and employ 
OXPHOS for survival will be killed at lower concentrations of drug.   
 
3.) Determine the role of DxR-induced mitochondrial fusion in the activation and 
differentiation of primary t-cells. Buck et al determined that mitochondrial 
morphology dictates naïve T cell differentiation and fate, a novel paradigm in 
immuno-metabolism. As such, many studies of chemotherapy-induced 
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immunosuppression have not yet examined the effects of chemotherapy on naïve t-
cell activation and differentiation. Identifying this role, particularly in the context of 
drug-induced mitochondrial remodeling, can be very useful in addressing those 
important gaps of knowledge. For example, our preliminary data indicate that TH17 
cells possess fissed mitochondria, as do mature Jurkat T cells. In those same Jurkats, 
DxR administration induces mitochondrial fusion, and we hypothesize that DxR 
treatment will likewise induce mitochondrial fusion and inhibit the differentiation of 
Th17 cells, among many other effector types. 
 
B. BACKGROUND AND SIGNIFICANCE 
 
Cancer & Chemotherapies 
 
Leukemias are a group of blood cancers that are among the most common in the 
world, affecting over 4.3 million people globally. Standard of care treatments routinely 
incorporate the CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) 
chemotherapy regimen, which includes the intercalating anthracycline DxR. While useful 
in treating early- to mid-stage lymphomas (curative in 40% of cases), sustained DxR-
inclusive CHOP doses also present significant side effects to patients, including dilated 
cardiomyopathy, congestive heart failure, and death. In fact, clinical outcome studies 
have found between 8% (1) and 50% of chemotherapy patients die within 30 days of 
initial administration, suggesting pharmacological causes of death, rather than disease 
progression (2). Importantly, most common chemotherapeutic molecules are also potent 
immunosuppressors, sending 60,000 US cancer patients to the hospital each year (3) on 
account of depressed white blood cell counts precipitating a serious infection. 
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T Cell Fate & Mitochondria 
 
Prior analyses have shown that t-cell fate is inexorably driven by the morphology 
and action of mitochondria, and in particular their functional dynamics in oscillating 
between fused hypernetworks (using catabolic metabolism) and fission-based 
independent organelle arrangements (employing anabolic metabolism) (4). Specifically, 
Buck et al found that modulation of the GTPase protein mediators of mitochondrial 
dynamics, mitofusins and DRP-1, effectively and deterministically altered the 
differentiation of CD4+ T-cells into either a memory or effector morphology (Figure 1). 
CD4+ effector T cells, which are a broad class of T cells (i.e., Th1, Th2, and Th17 cells) 
that dramatically proliferate in actively responding to immune threats  are known to 
contain fissed mitochondria, likely for rapid biosynthesis via the glycolytic pathway, 
while memory t-cells have been shown to fuse their mitochondria, perhaps for sustained 
energy production through oxidative phosphorylation (5). Currently, the effects of 
standard of care chemotherapies on naïve T cell activation and subsequent differentiation 
through the mitochondria remain poorly characterized, especially in regards to 
mitochondrial response physiology and immunosuppression. 
 
Mitochondrial Dynamics and Remodeling 
 
Mitochondria are dynamic, double-membrane bound hubs of bioenergetics, cell 
signaling, and redox balance that exist as an oscillating network of fused superstructures 
and smaller, single organelles. Their position at the junction of catabolic and anabolic 
metabolism is thought to connect these morphological changes to larger cellular 
metabolic programs, which in turn has implicated mitochondrial dynamics and the 
proteins associated with them in a number of disease states. For example, the GTPase 
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dynamin related protein (DRP-1), when phosphorylated at its serine 616 moiety, localizes 
with the Mitochondrial Fission Factor (Mff) at the outer mitochondrial membrane 
(MOM), dividing targeted mitochondria at scission sites to induce a fragmented network 
morphology. While beneficial as an intercessor of mitophagy, altered expression of DRP-
1 has been implicated in a number of disease phenotypes, including diabetes, 
neurodegeneration, and cardiovascular disease.  
Mitochondrial fusion, on the other hand, is mediated differentially through both 
its inner and outer membranes. The GTPase mitofusin proteins (MFN-1,2), when 
dimerized either homo- or hetero-typically, function to merge the MOM, while the 
GTPase optic atrophy (OPA-1) facilitates the inner mitochondrial membrane (MIM) of 
fusing mitochondria. Fused mitochondria resulting from the action of these proteins form 
super networks through which substantial complementation can occur, including the 
transfer and supplementation of mtDNA, proteins, and metabolites. However, as with 
DRP-1, altered expression of fusion mediators has been connected to a diverse set of 
diseases, diabetes, obesity, neurodegeneration, heart failure, and muscle atrophy among 
them.  
Generally, the role of mitochondria in mediating intrinsic apoptosis (and in 
chemotherapy resistance) has been broadly examined via mitochondrial outer membrane 
permeabilization (MOMP), a critical event during which cytochrome C embedded in the 
MIM is freed to associate with cytosolic apoptotic caspases and drive cell death. While 
both useful and illustrative, such analysis has thus far failed to capture the following:  
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1) The role that important proteins, including mitochondrial dynamics and 
morphology mediators, play in specific chemotherapy-cancer resistance 
paradigms, including CHOP and NHLs. 
2) How mitochondrial and metabolic dynamics within these models, including 
associated oxidative phosphorylation and glycolytic metabolic schemes, alter or 
influence blood cancer cell adaptation and survival post-chemotherapy assaults 
3) What impacts chemotherapy-induced mitochondrial remodeling has on important 
T cell physiology, especially their differentiation. 
 
In continuing our studies in addressing these gaps, and using our prior data as a basis, 
we hope that successful completion of our work will reveal new and important 
mitochondrial protein targets in chemotherapy sensitivity/efficacy, as well as elucidate 




As we previously mentioned, many common chemotherapeutic molecules are also 
potent immunosuppressors, sending 60,000 US cancer patients to the hospital each year 
(3) on account of depressed white blood cell counts precipitating a serious infection. Of 
these patients, 1 in 14 will perish from such immunosuppression complications (6). 
Recent studies have elucidated potential mechanisms for compromised immune function 
and competence in chemotherapy exposed physiology, including a reduction in the levels 
of circulating CD8+, NK, Th2, Th17, and Treg cells in patient vasculature (7). However, 
these studies account only for proliferation numbers and viability post-chemo 
administration, which while important in understanding immune cell responses to anti-
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cancer medicines, neglects an important and under-examined dimension of chemo 
response: t-cell fate and differentiation. 
As such, using our preliminary work with chemotherapy and the mitochondria of 
mature Jurkat t-cells, along with recent findings by Buck et al, we propose a novel 
mechanism of immunosuppression. Acting concurrently with the widely accepted 
cytotoxicity of chemotherapies to immune cells, we submit that chemotherapy-induced 
modulation of important mitochondrial dynamics suppresses immune cell differentiation 
and subsequent ability to respond to immunological threats in-vivo.  
 
D. PRELIMINARY DATA 
 
Our recent findings support our hypothesis that chemotherapy-induced modulation of 
mitochondrial dynamics suppresses effector T cell differentiation and subsequent ability 
to respond to immunological threats in part through study of the relationship of 
mitochondrial remodeling and the chemotherapeutic agent doxorubicin within a mature, 
differentiated Jurkat in-vitro model (Specific Aim 1). Specifically, doxorubicin was 
administered to a Jurkat cell culture in concentrations of 0, 0.5 µM, and 1.0 µM for a 
treatment interval of 24 hours (Figure 1). Western blot analysis revealed a considerable 
increase in all electron transport chain (ETC) complexes in DxR treated cells compared 
to control, with ATP Synthase (Complex V) demonstrating a significant 10-fold increase 
in expression. The GTPase proteins responsible for the fusion of the outer mitochondrial 
membrane, Mfn-1,2, were found to have increased abundance, while DRP-1, responsible 
for mitochondrial fission, was shown to be decreased. Quantitative PCR analysis showed 
a significant decrease in DRP-1 expression from control to 1.0 µM of DxR and a 
significant increase in Mfn-2 and OPA-1 expression from control to 1.0 µM at 24 hours 
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(Figure 2). Taken together, our initial studies suggest that DxR administration promotes 
mitochondrial fusion and OXPHOS in Jurkat t-cells, while untreated Jurkats continue to 




















Figure 1.  
Figure 2.  
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Data collected through the use of a Clark-type oxygen electrode suggested that DxR 
treated cells respire at an increased rate relative to control (an approximately 3x increase) 
(Figure 3), while comparable respiratory control ratios for DxR treated and control cells 
(2.9 and 2.94, respectively) appear to indicate tight mitochondrial coupling (Figure 4). 
Taken together, our data indicate that mitochondrial oxidative phosphorylation, normally 
de-emphasized in cancer cell physiology, is employed at greatly increased rates under 
DxR treatment, and with it, a selective preference for fused mitochondrial morphology. 
The nature of the role of this sort of mitochondrial response to chemotherapy in 
activating/differentiating t-cells in-situ remains unknown or under-reported, despite its 
potentially important implication in chemotherapy efficacy, resistance, and 
immunosuppression. Attempting to address that dearth, our preliminary data shows, for 
the first time to our knowledge, that mitochondrial fission regulator DRP-1 is 
significantly upregulated in Th17 differentiated primary spleen t-cells (compared to an 
activated undifferentiated control), suggesting a fissed mitochondrial phenotype (Figure 
5). In addition, we found that this relative abundance of DRP-1 RNA was also seen in 
differentiated Th1 and Th17 cells compared to an activated-but-undifferentiated control 
(Figure 6). Our insight into the endpoint abundance of mitochondrial morphology 
mediator proteins (and subsequent mitochondrial morphology) in Th0s, Th1s, Th17s 
differentiated from naïve t-cells provides us states with which to compare primary t-cells 
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Figure 5.  





Specific Aim 1: Demonstrate changes in mitochondrial morphology and metabolic 
reprograming in surviving doxorubicin (DxR)-applied cancer cells, and identify the 
protein mediators employed for that survival.  
 
Rationale: The goal of this specific aim is to identify the potential proteins utilized by 
leukemias/mature cancerous t-cells to survive small-molecule chemotherapy assaults 
(DxR), as well as provide possible protein targets that allow for increased sensitivity to 
chemotherapies, beginning with doxorubicin (DxR). 
 
1.1 Establish DxR toxicity to Jurkat culture/ human leukemia lymphoblasts. A 
culture of Jurkat leukemia cells (ATCC) will be raised and cultured according to widely 
used and well-cited culture protocols: RPMI 1640 media (ThermoFisher/Gibco), 
completed with PenStrep (ThermoFisher) and FBS (Omega Scientific) in compositions of 
2% and 10% percent by volume, respectively. 5 condition states will be parsed from this 
initial culture: control, vehicle/DMSO (Sigma), doxorubicin/DxR (Sigma) low 
concentration (LD25), DxR mid concentration (LD50), and DxR high concentration 
(LD75). To assess drug toxicity and subsequent cell viability at 3 time points (1 hour, 6 
hours, 24 hours), we will incorporate proliferation assays, including 0.4% trypan blue 
(Sigma) inclusion and flow cytometry using both Annexin V and DNA fragmentation 
parameters. Results from these assays will be used to establish baseline proliferation 
metrics for control Jurkats and assess the extent of toxicity of escalating DxR dosing at 
each time point. We expect initial toxicity data to corroborate our preliminary findings in 
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establishing an appropriate dosing regimen for further experiments. Viability assays will 
be performed at least 3 times to determine appropriate DxR dose concentrations with 
greater accuracy and precision through standard deviation. 
 
Potential problems and alternative approaches 
It is possible that our selected assays for cell viability and proliferation may yield 
inconsistent or imprecise results. Should we need further validation for DxR toxicity 
and/or cell viability proliferation, we can use alternative methods, including tetrazolium 
reduction (MTT), luciferase assays, or fluorescent nucleic acid staining (SYTOX). 
 
1.2. Characterize DxR-induced mitochondrial dynamics in jukrat/leukemia. All 5 
conditions will be collected at each time point for a total sample set of 15 (Ctrl, Vehicle, 
DxRlow, DxRmed, DxRhigh for 1, 6, and 24 hours) and prepared for western 
immunoblotting. We will probe for direct mitochondrial GTPase morphology mediators, 
including dynamin-like protein 1 (DRP-1), mitofusins 1 and 2 (MFN-1, 2), and optic 
atrophy 1 (OPA-1), all from Cell Signling) and assess protein abundance differentials 
between condition states qualitatively (banding) and quantitatively via densitometry 
(NIH). To corroborate protein abundance, we will isolate RNA and subsequently perform 
real-time PCR for the same gene targets in-vitro using primers from IDT. Visualization of 
these morphological adaptations and changes will be achieved through confocal 
fluorescent microscopy using MitoTracker Deep Red FM dyes (ThermoFisher). Given 
our preliminary western immunoblot data, we expect to see morphological changes 
consistent with decreases of DRP-1 and increases in MFN-2; specifically, we anticipate 
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observing the inducement of a highly fused, perhaps even tubular, mitochondrial 
network. 
 
Potential problems and alternative approaches 
Western immunoblotting will be used to assess changes in mitochondrial fusion and 
fission, along with associated densitometry. However, it is possible that mitochondrial 
dynamics in our Jurkat cells may result more from spatial localization of protein 
mediators than their total abundance, making band differences too slight or subtle to 
detect qualitatively. Should this be the case, we plan to label the following components of 
mitochondrial dynamics and visually observe their respective changes through 
immunofluorescence: MFN-2, OPA-1, and pDRP-1 (Cell Signaling), as well as 
mitochondrial morphology with MitoTracker Deep Red (ThermoFisher) 
 
1.3. Determine the effects of all doses of DxR on cell metabolic programming. First, 
    ,  ,     
proteins: for example, each respiratory complex via an OXPHOS antibody (Cell 
Signaling) and pyruvate dehydrogenase (Cell Signaling) for glycolytic metabolism. 
Mitochondria that are fragmented or fractured exhibit less electron transport coupling, 
less employment of oxidative phosphorylation/oxygen consumption (measured in nmol 
oxygen/min/mg), and thus a lower respiratory control ratio (RCR). To assess the 
phenomena of mitochondrial respiration and its relation to DxR assault survival, we will 
examine mitochondrial coupling and fragmentation through oxygen respiration with a  
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clark-type electrode and digitonin-permeabilized cells (Hansatech Instruments). Rates of 
mitochondrial respiration as measured by oxygen consumption will provide insight into 
the extent to which the mitochondria of DxR treated cells employ oxidative 
phosphorylation. Similarly, the RCR of that respiration is used to indicate the extent of 
mitochondrial ETC coupling. Our preliminary data suggests that we will observe 
increases not only in mitochondrial respiration rate, but also in RCR, corroborating our 
immunoblot data that DxR induces mitochondrial fusion and oxidative phosphorylation 
in Jurkat cells. Finally, we will support our protein expression findings with further qPCR 
analysis for each gene examined through immunoblotting. 
 
Potential problems and alternative approaches 
Our lab has generated preliminary data in support of this experiment, both with 
doxorubicin changes to both OXPHOS expression and mitochondrial respiration, and we 
do not anticipate any potential problems. 
 
Specific Aim 2: Determine the role of protein mediators of mitochondrial 
morphology and metabolic reprograming in chemotherapy survival and sensitivity 
via modulation of expression of those protein mediators.  
 
Rationale: Specific Aim 1 seeks to elucidate protein targets involved in leukemia cell 
survival. In this specific aim, the effect of those protein targets in chemotherapy survival 
will be determined through their modulation via CRISPR KO technology. In particular, 
this aim will uncover whether these proteins are critical to cell survival, and thus serve as 
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targets in developing pre-treatments, other knockouts, and inhibitors to increase DxR 
sensitivity.  
 
2.1. Characterize the role of mitochondrial dynamics mediators on cell survival post 
DxR administration. We will suppress mitochondrial fusion via the introduction of a 
CRISPR/Cas9 mitofusin-2 knockout (KO) plasmid from Santa Cruz Biotechnology; the 
UltraCruz transfection reagent will serve as a vehicle, and untreated Jurkat cells will 
function as a control. Uptake of CRISPR plasmid/ inhibition of mitofusin 2 will be 
validated through immunoblot (using Cell Signal antibodies) and flow cytometry. The 
untreated control, transfection reagent vehicle, and DxR-treated sets (LD25, LD50, LD75) 
will be tested for proliferation and viability at the same time points as in Specific Aim 1 
(1hr, 6hrs, 24hrs) using trypan blue inclusion and flow cytometry/annexin V assays. In 
doing so, we will test our hypothesis that fused mitochondria and oxidative 
phosphorylation-driven metabolism are crucial to Jurkat cancer cell survival and 
desensitization. Specifically, we will compare dosing concentrations of DxR required to 
achieve LD25,50,75  in the MFN-2 KO groups to the dose concentrations that achieved the 
same toxicity in the non-KO groups. Conversely, we will promote mitochondrial fusion 
in an additional group through the action of the M1 Fusion Promoter (Sigma Aldrich), 
and run similar viability/proliferation assays to determine the protective effect of durable 
mitochondrial fusion in relation to DxR dose toxicity. 
 
Confocal fluorescent microscopy will be used to visualize mitochondrial morphology 
changes in all groups at all time points to corroborate immunoblot data, as well as to lend 
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insight into the spatial properties of mitochondria that have been morphologically 
modulated through CRISPR and small-molecule drug action.  
 
Mitofusin-1 and mitofusin-2 expression levels are known to vary across tissues (MFN-1 
   , , ,  ,  lar tissue (8,9) for 
example, while MFN-2 is preferential in skeletal muscle, brain, and brown adipose tissue 
(8,10). Though our preliminary data suggests otherwise, it is possible that MFN-1 may be 
more directly involved in Jurkat mitochondrial fusion than MFN-2 (or may even rescue 
fusion function in the absence of MFN-2), leading to little or no mitochondrial fusion and 
subsequently no impact on cell sensitivity. In this case, we will simultaneously reduce 
MFN-1 with a CRISPR/Cas9 mitofusin-1 knockout (KO) plasmid from Santa Cruz 
Biotechnology, effectively inhibiting MFN-1-mediated fusion. Additionally, other 
methods of gene silencing (ASO, siRNA) are available should CRISPR transfection be 
unreliable or ineffective. 
 
Specific Aim 3: Determine the role of DxR-induced mitochondrial fusion in the 
differentiation of primary CD4 T cells.  
 
Rationale: Current studies of chemotherapy-induced immunosuppression are founded on 
t-cell viability and abundance post chemotherapy administration, but not on the effects of 
chemotherapy on T cell differentiation, particularly in the context of drug-induced 
mitochondrial remodeling. Identifying this role presents a platform for wide applicability, 
as changes in the mitochondria of differentiating T cells can have irrevocable effects on 
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their fate or final phenotype. Our preliminary data shows that Jurkat T cells treated with 
doxorubicin begin to switch from fissed to fused mitochondria via a decrease in DRP-1, 
resulting in their demise. In addition, we show that Th17 cells have an increase in DRP-1, 
which is indicative of having fissed mitochondria. Th17 cells are crucial in the removal 
of fungal infections, a type of infection that is increased in cancer patients following 
chemotherapy treatment. Due to our preliminary findings we hypothesize that 
doxorubicin inhibits the differentiation of effector T cells by inhibiting the activation of 
DRP-1. Our studies would provide a mechanism for the susceptibility of opportunistic 
infections to cancer patients following chemotherapy.  
 
3.1 Characterization of mitochondrial dynamics in CD4 T cell subsets. Previously, 
Buck et al found that memory T cells contain fused mitochondria and effector T cells 
contain fissed mitochondria. Effector T cells are either activated CD8 T cells or activated 
CD4 T cells. Here we focus on CD4 effector T cells, which are also known as helper T 
(Th) cells. CD4 effector T cells can be broken down into 3 subsets of effector T cells: 
Th1, Th2 or Th17 cells. Th1 cells help in the removal of viruses and intracellular 
bacteria. Th2 cells are involved in the removal of parasites. Th17 cells aid in the removal 
of fungal infections. Buck et al did not look at specific subsets of CD4 effector T cells 
and instead focused on effector T cells as a whole, not distinguishing between CD4 and 
CD8 effector T cells. Therefore, in this aim we would like to determine if Th2, Th1, and 
Th17 cells have fissed mitochondria prior to looking at the effects of doxorubicin on CD4 
T cell differentiation. We will also evaluate the mitochondria of regulatory T (Treg) cells 
since their mitochondrial dynamics have not been elucidated. Treg cells are not called 
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effector T cells because their role is to suppress overexuberant effector T cells. Buck et 
also showed that memory T cells have fused mitochondria, which may be due to using 
oxidative phosphorylation to produce energy. Similarly, Treg cells mostly utilize 
oxidative phosphorylation to generate energy. Therefore, we hypothesize that Treg cells 
will have fused mitochondria whereas effector T cells will have fissed mitochondria. 
Effector T cells divide much more rapidly than Treg cells and thus have greater energy 
demands. The fissed mitochondria allow the rapidly dividing effector T cells to increase 
glycolysis in order to divert glycolytic intermediates into biosynthetic pathways for the 
production of macromolecules and organelles, which are necessary for cell proliferaiton. 
Once we confirm our hypothesis that effector T cells contain fissed mitochondria and 
Treg cells contain fused mitochondria, we will look at the effects of doxorubicin on T cell 
differentiation.  
  To determine the mitochondria dynamics of CD4 T cells subsets we will 
differentiate mouse naïve CD4 T cells into Th1, Th2, Treg, and Th17 cells and look at 
their mitochondrial morphology via protein analysis. Briefly, spleens will be isolated 
from the mice to set up T cell differentiation cultures. Using a CD4 T cell isolation kit 
(Invitrogen) we are able to isolate 20 million CD4 T cells from one spleen. We will use 
the 20 million CD4 T cells to differentiate 4 million CD4 T cells into Th0, Th1, Th2, 
Treg and Th17 cells. Since we want to run the T cell differentiation assay in triplicate and 
repeat the experiment at least 3 times to achieve statistical significance, we will need 
about 10 mice for this study. We will be using T cell differentiation kits (R&D systems) 
to generate Th1, Th2, Treg and Th17 cells in vitro. Th0 cells are CD4 T cells that are 
activated with anti-CD3 and anti-CD25, but that are not differentiated and thus are used 
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as a control. Following T cell subset generation, a fraction of the cells will be analyzed to 
validate that the differentiation into each subset worked via flow cytometry as described 
below (aim 3.2). Next, the cells will be prepared for western blot analysis. For western 
blot analysis we will be analyzing the amount of mitochondria fission via the active form 
of DRP-1 (phospho-DRP-1) and fusion via MFN-2 and OPA-1 proteins in the 
differentiated T cells. We expect to see increased levels of phosphor-DRP-1 compared to 
MFN-2 and OPA-1 in Th1, Th2 and Th17 cells and the contrary in Treg cells.  
 
Potential problems and alternative approaches 
It is possible that we may not be able to detect significant differences in levels of 
expression between DRP-1 and MFN-2/OPA-1 proteins. Therefore, it may be difficult 
via western blot analysis to determine if the different subsets of CD4 helper T cells 
contain fissed or fused mitochondria. Due to this possibility, we will utilize confocal 
microscopy to visualize the fused and fissed mitochondria in the different subsets of CD4 
helper T cells. Briefly, following differentiation of the four subsets of CD4 helper T cells, 
the cells will be stained with fission and fusion markers, including fluorescent antibodies 
for MFN-2, OPA-1, and DRP-1 (Cell Signaling). In addition, mitochondrial morphology 
will be simultaneously assessed through use of MitoTracker Deep Red FM dye 
(ThermoFisher). Both will be accomplished by introducing the fluorescent tags to 
respective cultures of Th0, Th1, Th2, Th17, and TReg cells that have been differentiated 
from naïve mouse CD4 T cells in chamber slides. After application of the dyes, cells will 
be fixed and visually assessed through confocal microscopy. 
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3.2. The effects of doxorubicin on CD4 helper T cell differentiation. To determine the 
effects of doxorubicin on CD4 helper T cell differentiation, doxorubicin will be 
administered to cultures of in-vitro mouse T cell differentiation assays. Following this in-
vitro assay, the extent of activation and differentiation into T cell subsets (Th1, Th2, 
Treg, and Th17) in the presence and absence of doxorubicin will be compared using flow 
cytometry analysis.  
 To facilitate our studies, we will utilize C57BL/6J male mice that are 
commercially available (Jackson Laboratory). Briefly, spleens will be isolated from the 
mice to set up T cell differentiation cultures. Using a CD4 T cell isolation kit (Invitrogen) 
we are able to isolate 20 million CD4 T cells from one spleen. We will use the 20 million 
CD4 T cells to differentiation 5 million CD4 T cells into Th0, Th1, Th2, Treg and Th17 
cells. Since we want to run the T cell differentiation assay in triplicate and have vehicle 
and doxorubicin treatments at 3 doses (0.5, 0.75 and 1 uM), we will need a total 12 mice 
for each experiment. To achieve statistical significance, we will need to repeat this 
experiment 3 times. Therefore, we will need a total of 36 mice to carry out this study. We 
will be using T cell differentiation kits (R&D systems) to generate Th1, Th2, Treg and 
Th17 cells in vitro. Th0 cells are CD4 T cells that are activated with anti-CD3 and anti-
CD4 but not differentiated and are used as a control. During T cell differentiation set up, 
doxorubicin will be added at the indicated doses for 72 hours, at which point T cell 
differentiation medium will be refreshed without doxorubicin. T cell differentiation will 
be analyzed on day 5 using flow cytometry.  
In order to check for differentiation into each subset using flow cytometry, cells 
will be first stimulated in the presence of brefeldin A (eBioscience), 40 ng/mL phorbol 
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12-myristate 13-acetate, and 1 ug/mL inomycin (Sigma-Aldrich) for 4 hours at 37°C. 
This stimulation will allow for the production of IFN-gamma from Th1 cells and IL-17A 
from Th17 cells. All cells will then be stained with fluorochrome-tagged antibodies 
against cell surface markers CD4, CD44, CD62L, Annexin V. Following cell surface 
staining, cells will be fixed and permeablized to allow for intracellular staining. Th1 cells 
will be stained with the flurochrome-tagged antibody against IFN-gamma, Th2 cells will 
be stained with the flurochrome-tagged antibody against IL-4, Treg cells will be stained 
with the flurochrome-tagged antibody against FOXP3, and Th17 cells will be stained 
with the flurochrome-tagged antibody against IL-17A. All antibodies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
for flow cytometry analysis will be purchased from Biolegend. Data will be collected on 
a BD Accuri C6 plus cytometer using FACSDiva (BD Bioscience) software, followed by 
FlowJo (Tree Star) analysis. 
 Our preliminary data indicates that doxorubicin may alter mitochondrial dynamics 
in surviving Jurkat T cells, forcing them from fissed to fused mitochondrial morphology 
via a decrease in DRP-1 and consequently an increase in MFN-2, to survive. We also 
observe an increase in DRP-1 in Th17 cells, indicating that Th17 cells have fissed 
mitochondria as well. Due to our preliminary findings, we hypothesize that doxorubicin 
inhibits the differentiation of effector T cells by inhibiting the activation of DRP-1. The 
results from this study will support our hypothesis that doxorubicin inhibits the 
differentiation of effector CD4 T cells, also known as helper T cells, by inhibiting the 
activation of DRP-1. Moreover, it provides a mechanism for the immunosuppression 
observed in cancer patients following chemotherapy with doxorubicin.  
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Potential problems and alternative approaches 
Since doxorubicin is toxic to cells, one potential problem we may have is issues in 
differentiation of the subsets of CD4 helper T cells due to an increase in cell death 
following doxorubicin administration. The doses of doxorubicin chosen to administer 
during the differentiation assay were determined based on our preliminary data using 
Jurkat T cells. To address this potential issue, we will try different concentrations of 
doxorubicin during the differentiation assays. We will also try adding doxorubicin for 
different amounts of time, since the amount of time may also lead to increased cell death 
and interfere with our differentiation assay. If all else fails, we plan to obtain blood 
samples from cancer patients following their chemotherapy treatment and analyze their 
percentages of Th1, Th2, Treg and Th17 cells compared to blood samples from healthy 
individuals using flow cytometry analysis as described above.  
 
 
STATEMENT OF CANCER RELEVANCE 
 
T-cell leukemias are a group of blood cancers that are among the most common in 
the world, affecting over 2.3 million people globally and causing 353,000 deaths annually 
(11,12). Notably, leukemia is the most common pediatric cancer (13). Standard of care 
treatments incorporate the CHOP (14)  (cyclophosphamide, hydroxydaunorubicin, 
oncovin, prednisone) chemotherapy regimen, which includes doxorubicin (DxR). While 
useful in treating early- to mid-stage leukemias, the doses of DxR found in common 
treatment regimens present significant side effects to patients, including congestive heart 
failure and death. Moreover, cancers exposed to repeated doses of chemotherapy, as well 
as recurrent cancers, become desensitized to further applications of chemotherapy drugs. 
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This is significant, as lymphoblastic leukemia has a relapse rate of up to 25% in children 
(15,16,17,18), dramatically worsening their prognoses, with survival rates dropping to 
between 50-15% (19, 20, 21, 22, 23). 
Additionally, most common chemotherapeutic molecules, including doxorubicin, 
are potent immunosuppressors, sending 60,000 US cancer patients to the hospital each 
year due to secondary illnesses or infections (3);  of these patients, 1 in 14 will perish 
from such complications (6). Studies searching for potential mechanisms of compromised 
immune function by chemotherapy are largely predicated on the idea that cells 
responsible for immune system functionality are killed by chemotherapy, thus lead to 
immunosuppression.  
Through our novel work with mitochondria, however, we propose a new 
mechanism by which leukemia cells are desensitized to chemotherapy, as well as an 
undiscovered mechanism of immunosuppression rooted in the response of mitochondria 
in undifferentiated t-cells to chemo, inexorably changing their fate in the fight of the 
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